MY NAME IS AMY WILLIAMS I'M THE
DIRECTOR OF THE ADVOCACY OFFICE
AND WELCOME TO THE 87th MEETING
OF THE ADVOCACY BOARD AND OF THE
NCRA.
I SEE A LOT OF NEW FACES.
THIS IS TERRIFIC.
WE WILL BE WELCOMING NEW MEMBERS
HERE TO THE BOARD.
WE'LL HOLD INTRODUCTIONS TOWARDS
THE END OF THE MEETING.
WE'LL GET STARTED RIGHT AWAY BUT
IT'S NICE TO SEE SOME FAMILIAR
FACES FROM THE PAST AND NEW
FACES AND AS ALWAYS OUR EXISTING
BOARD MEMBERS.
I'LL TURN IT OVER TO ANNIE IN A
MINUTE BUT WANTED TO GIVE A
SPECIAL SHOUT OUT TO ANNIE AND
WELCOME HER TO HER FIRST MEETING
AS OUR BOARD CHAIR.
WE HAVE WORKED WITH HER OVER THE
PAST COUPLE MONTHS TO PREPARE
FOR TODAY AND I THINK WE HAVE A
TERRIFIC AGENDA FOR YOU ALL.
SO AS ALWAYS, THANKS FOR JOINING
I'LL LET ANNIE GET US START AND
AS A REMINDER FOR ALL OF YOU,
WE'LL HAVE TIME AT THE END TO DO
ADMINISTRATIVE BUSINESS FOR THE
BOARD AND THAT WILL GIVE US A
CHANCE FOR YOU ALL TO ALSO
INTRODUCE YOURSELVES TO EACH
OTHER.
DUE TO TIME CONSTRAINTS WE
COULDN'T START THAT WAY TODAY
BECAUSE WE HAVE A NICE AGENDA OF
SPEAKERS FOR YOU AND NEED TO GET
RIGHT INTO THE AGENDA BUT WE'LL
MAKE TIME FOR THAT AT THE END.
WITH THAT, ANNIE, THANK YOU FOR
CHAIRING YOUR FIRST MEETING AND
GETTING US HERE TODAY AND I'LL
TURN IT OVER TO YOU.
>>THANK YOU, SO MUCH AND THE
WHOLE STAFF AT OAR WHO HELPED ME
GET READY AND I'M EXCITE ABOUT
OUR SPEAKERS TODAY AND ALL WE'RE
GOING TO LEARN.
I'D LIKE TO CALL THIS MEETING TO
ORDER AND IT'S MY TURN TO READ
THE OPENING STATEMENT.
SO AS COMMITTEE MEMBERS I WANT
TO REMIND YOU THAT WE MUST
ABSENT OURSELVES DURING SPECIFIC
DISCUSSIONS WHENEVER YOUR
PARTICIPATION AND DELIBERATIONS
ON A PARTICULAR PRODUCT, PROGRAM
OR OTHER SPECIFIC MATTER WOULD
CONSTITUTE A CONFLICT OF
INTEREST OR CREATE AN APPEARANCE
OF ONE.
IT'S INCUMBENT UPON YOU TO
ADVISE THE EXECUTIVE SECRETARY
AND ABSTAIN FROM ANY
PARTICIPATION OR DISCUSSION OR
ACTION REGARDING THAT MATTER.
IN LIGHT OF THE CURRENT POLICIES
GOVERNING CONFLICT OF INTEREST
BASED ON FINANCIAL HOLDINGS OF
SPECIAL GOVERNMENT EMPLOYEES WE
MUST DEPEND ON YOU TO
VOLUNTARILY ABSENT YOURSELF
DURING ANY AND ALL DISCUSSION ON
MATTERS THAT COULD CONCEIVABLY
IMPACT THE STATUS OF THESE HOLD.
WE TRUST YOUR JUDGMENTS IN THESE
INSTANCES.
BY LAW, A QUORUM OF BOARD
MEMBERS IS REQUIRED FOR EACH
INSTANCE IN WHICH A VOTE OCCURS
IN AN OPEN SESSION.
DURING THIS MEETING A MINIMUM OF
SIX POINTED MEMBERS MUST BE
PRESENT TO VOICE THEIR VOTES.
NEW MEMBERS WHO ARE NOT CURRENT
MEMBERS OF ANOTHER NCI ADVISORY
BOARD ARE NOT VOTING UNTIL THEY
HAVE BEEN CLEARED BY THE NCI
ETHICS OFFICE AND THE OFFICE OF
HUMAN RESOURCES.
NOW I'M GOING READ THE PUBLIC
COMMENT STATEMENT.
MEMBERS OF THE PUBLIC WHO MAY
WISH TO EXPRESS VIEWS DURING
ITEMS DURING THE MEETING MAY DO
SO IN WRITING BY WRITING AMY
WILLIAMS THE EXECUTIVE SECRETARY
WITHIN 10 DAYS.
ANY WRITTEN STATEMENTS WILL
RECEIVE CAREFUL CONSIDERATION.
SO I'M JUST EXCITED THAT WE'RE
ALL HERE TOGETHER AND OUR --
AMY, DO YOU HAVE ANY
HOUSEKEEPING REMINDERS?
>>SURE, FOR THOSE WHO ARE NEW
AND AS A REMINDER FOR THE
MEMBERS WHO HAVE BEEN WITH US
FOR A LITTLE WHILE WE'D LIKE TO
ENCOURAGE AN INTERACTIVE
DISCUSSION BETWEEN THE BOARD
MEMBERS AND PRESENTERS IN LINE
WITH THAT, IF YOU HAVE QUESTIONS
FOR THE PRESENTERS, SEND THEM TO
ME IN THE CHAT OR POST THEM IN
THE CHAT AND YOU CAN ALSO RAISE
YOUR HAND WHEN THE PRESENTER
CONCLUDES AND ANNIE AND I WILL
DO OUR BEST TO TRIAGE THOSE
QUESTIONS AND IF THERE ARE ANY
WE CAN'T GET TO DUE TO TIME
CONSTRAINT OR THE TOPIC, THE
ADVOCACY OFFICE CAN FOLLOW-UP
WITH YOU.
AND OUR FIRST PRESENTER IS A
PERFECT MODEL FOR INTERACTION.
WE HAVE OUR ACTING DIRECTOR,
DR. LOWY JOINING US.
I'LL LET ANNIE INTRODUCE HIM BUT
HE WILL PRESENT AND CAN TAKE
SOME QUESTIONS AT THE END.
AS ALWAYS WE'RE SO EXCITED TO
HAVE THE ACTING NCI DIRECTOR'S
UPDATE GIVEN BY DR. DOUG LOWY
HIMSELF.
THANK YOU SO MUCH, DR. LOWY FOR
TAKING THE TIME TO BE WITH US
TODAY.
WE'RE SO EXCITED TO HEAR YOUR
UPDATE.
>>GOOD AFTERNOON.
IT'S A PLEASURE FOR ME TO MEET
WITH YOU THIS AFTERNOON AND
EVERYONE ELSE.
BEFORE I GET STARTED, I JUST
WANTED TO SAY THAT AT THE JUNE
MEETING ONE OF THE ISSUES YOU
RAISED WITH ME IS HOW YOU CAN
HAVE INPUT INTO THE CANCER
MOONSHOT.
THIS AFTERNOON CATHERINE YOUNG
IS GOING TO BE MAKING A
PRESENTATION FOR YOU AND IS FROM
THE WHITE HOUSE OFFICE OF
SCIENCE AND TECHNOLOGY POLICY
AND VERY INVOLVED WITH THE
MOONSHOT.
HOPEFULLY, YOU'LL HAVE A
CONSTRUC
CONSTRUCTIVE BI-DIRECTIONAL
DISCUSSION.
AND IN THE SAME VEIN, BEFORE I
GO FURTHER I MADE THE TITLE
ENDING CANCER AS WE KNOW IT FOR
ALL BECAUSE THIS IS VERY MUCH
THE THEME OF THE CURRENT
ADMINISTRATION.
IN MY FIRST SLIDE, I WOULD LIKE
TO WELCOME THE NEW MEMBERS OF
THE NCRA.
A
AND THIS IS FOR THOSE WHO LOOK
FORWARD TO YOUR BEING ACTIVE
MEMBERS AND ONE OF THE THINGS I
AM DOING TODAY IN MY
PRESENTATION IS TO INTRODUCE YOU
TO A COUPLE ASPECTS OF THE NCI
AND I'M SURE AS YOU GO FORWARD
THAT YOU WILL BECOME
PROGRESSIVELY MORE FAMILIAR WITH
THE NCI.
SO ANY WAY, THANKS SO MUCH FOR
YOUR WILLINGNESS TO JOIN AND
IT'S REALLY A TERRIFIC GROUP
THATTIE LEADS.
-- THAT ANNIE LEADS.
I'M GOING COVER A FEW TOPICS.
FIRST, NCI NEWS AND UPDATES AND
THEN A FEW SELECTED ADVANCES
FROM RESEARCH.
TALK AGAIN ABOUT THE CANCER
MOONSHOT.
I DISCUSSED THIS LAST TIME IN
JUNE AND THEN A BUDGET UPDATE.
SO IF WE CAN HAVE THE NEXT
SLIDE, MY DAYS ARE NUMBERED.
-- AS ACTING DIRECTOR BUT WE ARE
EXTRAORDINARILY FORTUNATE THAT
MONICA BERTOGNOLI WILL BECOME
THE PERMANENT NCI DIRECTOR AND
EXPECT HER TO BE SWORN IN AND
START NEXT WEEK AND EXPECT HER
TO HIT THE GROUND RUNNING.
AS MUCH AS I ENJOY BEING ACTING
DIRECTOR, IT'S CRITICALLY
IMPORTANT TO HAVE A
PRESIDENTIALLY APPOINTED
DIRECTOR FOR THE NCI ESPECIALLY
WITH AN ADMINISTRATION SO
INTIMATELY INVOLVED IN
SUPPORTING IMPROVED OUTLOOK FOR
PATIENTS WITH CANCER BOTH IN
TERMS OF CURRENT STANDARD OF
CARE AS WELL AS RESEARCH THAT
CAN LEAD TO NEW STANDARD OF CARE
AND I LOOK FORWARD TO
DR. BERTOGNOLI BECOMING THE NEXT
PERMANENT NCI DIRECTOR.
THIS IS THE CANCER CHILDHOOD
FORUM WHICH WE ATTENDED LAST
FRIDAY.
AND THIS IS A PHOTOGRAPH OF MANY
OF THE PEOPLE WHO WERE THERE.
IT WAS HELD BY THE WHITE HOUSE
AND REALLY WITH THE OFFICE OF
SCIENCE AND TECHNOLOGY POLICY
AND THERE WERE NCI PANELISTS,
GREG REMAN WHO BECAME THE
DIRECTOR FOR THE SCIENCE AND
CANCER INITIATIVE AND LOOK
FORWARD TO HIS ARRIVAL IN THE
NEAR FUTURE AND ANOTHER PANELIST
WAS STEVEN CHANNING THE DIRECTOR
OF THE NCI INTRAMURAL DIVISION
OF CANCER EPIDEMIOLOGY AND
GENETICS.
IT WAS A LIVELY MEETING WITH A
SERIES OF PANEL DISCUSSIONS AS
WELL AS SHORT VIGNETTES FROM
PEOPLE WHOSE LIVES HAD BEEN
TOUCHED BY CANCER, ESPECIALLY
CHILDREN'S LIVES TOUCHED BY
CANCER.
IN ADDITION, WE HAD THE AACR
CONFERENCE ON THE SCIENCE OF
CANCER HEALTH DESPAIRS IN RACIAL
AND ETHNIC MINORITIES AND THE
MEDICALLY UNDER SERVED IN
PHILADELPHIA THIS MONTH AND I
GAVE THE KEY NOTE ADDRESS THERE
AND I THOUGHT IT WAS SUMMARIZE
FOR YOU SOME OF THE TAKE-HOME
MESSAGES THAT I HAD.
SERVICE, ADDRESSING AND OVERCOME
CANCER HEALTH DISPARITIES HAS
BECOME HIGH PROFILE WITH GREATER
COMMITMENT AND THIS WAS
PALPABLE.
THERE WERE MORE PEOPLE AT THE
MEETING THAN EVER BEFORE.
AND THE EXCITEMENT WAS
EXTRAORDINARY.
WE'VE MADE SOME PROGRESS BUT WE
STILL HAVE A LONG WAY TO GO TO
ADDRESS THIS MULTIFACETED
PROBLEMS AND I TALKED ABOUT HOW
MORTALITY RATES HAVE BEEN GOING
DOWN FOR VIRTUALLY ALL GROUPS
EXCEPT FOR AMERICAN INDIANS AND
ALASKAN NATIVES AND I TOUCHED ON
UTERINE CANCER FOR HISPANIC AND
NATIVE WOMEN AND WE MUST BE
EXCLUSIVE IN THE CANCER RESEARCH
WORKFORCE AND I'LL GO BACK TO
THAT LATER IN THE PRESENTATION.
AND PERHAPS MOST IMPORTANT THAT
WE ALL HAVE A ROLE TO PLAY
WHETHER FOCUSSED ON THE UNITED
STATES OR LOW AND MIDDLE INCOME
COUNTRIES WHERE DISPARITIES ARE
EVEN GREATER THAN THE U.S.
I TRIED TO POINT OUT OUR ROLES
CAN SPAN A WIDE RANGE OF
RESEARCH AND CAN BE TECHNICALLY
ORIENT AND TECHNOLOGY
DEVELOPMENT AIMED AT REDUCING
DISPARITIES AND ALSO CAN BE
RESEARCH ON THE EFFECTED
POPULATIONS AND LOTS OF THINGS
IN BETWEEN.
I NOW WANT TO TALK ABOUT SOME
ADVANCES IN TERMS OF CANCER
RESEARCH AND THIS REALLY IS AN
ONGOING TESTIMONY TO THE
INCREASE IN SURVIVAL FOR CANCER
WHERE CANCER SURVIVORS NOW
REPRESENT 18 MILLION AND
PROJECTED TO BE 26 MILLION BY
2040.
THIS IS NOW MORE THAN 5% OF OUR
POPULATION AND A SUBSTANTIAL
INCREASE OF THE PERCENTAGE OF
THE POPULATION AS YOU CAN SEE
FROM THIS GRAPH WHERE WE WERE IN
THE MID 1970s TO WHERE WE ARE
NOW.
THIS SLIDE IS IMPORTANT FOR ALL
OF US BECAUSE IT ESSENTIALLY
HIGHLIGHTS MANY KINDS OF
PHYSICAL ACTIVITY CAN LOWER THE
RISK OF DEATH FOR OLDER ADULTS.
THIS WAS A STUDY IN ADULTS 59 TO
82 FOLLOWING THEM FOR MORE THAN
10 YEARS AND BASICALLY 2 1/2
HOURS OF MODERATE PHYSICAL
ACTIVITY WHICH IS WHAT 15 WOULD
BE SUBSTANTIALLY DECREASES THE
RISK OF DEATH AND IMPORTANTLY
REGARDLESS OF THE TYPE OF
ACTIVITY WHETHER YOU ARE SIMPLY
DOING WALKING, YOU'RE RIDING A
BICYCLE, RUNNING, WHATEVER IT
IS, THE MOST IMPORTANT THING IS
DO SOMETHING.
AND THESE IMPRESSIVE RESULTS ARE
BOTH FOR ALL-CAUSE MORTALITY,
CARDIOVASCULAR MORTALITY AND
CANCER MORTALITY RATES.
ANOTHER ISSUE IS THAT WE KNOW
THAT STOPPING SMOKING CAN
INCREASE LIFE EXPECTANCY BUT
WHAT ABOUT A HEALTHY LIFESTYLE.
DOES THAT HELP PEOPLE WHO HAVE
STOPPED SMOKING AND THIS ARTICLE
FROM THE DIVISION OF CANCER,
EPIDEEMEPI
DEEM
EPIDEEM IOLOGY -- EPIDEMIOLOGY
AND GENETICS SAYS YES.
ADOPTING A HEALTHY LIFESTYLE CAN
IMPROVE LIFE EXPECTANCY ON TOP
OF STOPPING SMOKING SO HERE'S
SOMETHING ELSE THAT CAN BE DONE
TO INCREASE LIFE EXPECTANCY.
AND THIS SLIDE TALKS ABOUT
SMOKING CESSATION IN CANCER
PATIENTS.
MANY PEOPLE DON'T REALIZE THAT
THERE IS AN IMPROVED OUTLOOK FOR
PATIENT WHO'S ARE CURRENT
SMOKERS IF THEY STOP SMOKING
WHEN THEY HAVE THEIR CANCER
DIAGNOSIS.
THEY'RE RESPONSE TO TREATMENT,
ETCETERA, ON AVERAGE WILL BE
BETTER AND THERE'S A TOBACCO
CONTROL MONOGRAPH PUBLISHED IN
JUNE I WOULD REFER YOU TO.
AND THIS IS IN THE AREA OF
CANCER TREATMENT AND WE KNOW HOW
DIFFICULT IT IS FOR WOMEN WHO
HAVE ADVANCED TRIPLE NEGATIVE
CANCER BUT THIS ADVANCE IS
ADDING THIS DRUG FOR
CHEMOTHERAPY CAN HELP WOMEN WITH
ADVANCED TRIPLE NEGATIVE BREAST
CANCER TO LIVE LONGER.
AND EVEN A FEW MONTHS OF ADDED
LIFE CAN SPELL A VERY BIG
DIFFERENCE IN TERMS OF WHAT
PEOPLE CAN DO WITH THEIR
REMAINING TIME AND SO I POINT
THIS OUT AS A SUBSTANTIAL
INCREASE.
.
THE BIDEN MOONSHOT INITIATIVE IS
ENDING CANCER AS WE KNOW IT FOR
ALL BECAUSE WE TO BE INCLUSIVE.
AND ON SEPTEMBER 12, PRESIDENT
BIDEN MADE A SPEECH CANCER
MOONSHOT HE ENTITLED ENDING
CANCER AS WE KNOW IT ON THE
ANNIVERSARY OF PRESIDENT
KENNEDY'S TALK ABOUT GOING TO
THE MOON THAT WAS 60 YEARS AGO
AND FITTINGLY AT THE JOHN F.
KENNEDY PRESIDENTIAL LIBRARY AND
BEATING CANCER IS SOMETHING WE
CAN DO TOGETHER.
I BELIEVE WE CAN USHER IN THE
SAME -- NEXT SLIDE, PLEASE,
NEXT.
AND THE SAME NATIONAL PURPOSE
THAT WILL SERVE TO ORGANIZE AND
MEASURE THE BEST OF OUR ENERGIES
AND SKILLS TO END CANCER AS WE
KNOW IT.
AND DURING THE PRESENTATION,
DURING HIS SPEECH THE PRESIDENT
MENTIONED AMONG OTHER THINGS,
THREE OF THE NCI NEW INITIATIVES
THAT ARE JUMP STARTING THE
CANCER INITIATIVE.
THE CANCER MOON SHOT SCHOLARS
PROGRAM, THE TELEHEALTH PROGRAM
AND MULTI-CANCER DETECTION.
YOU CAN LEARN MORE ABOUT THEM AT
THE CANCER.gov MOONSHOT.
I WANT TO MAKE SURE THAT YOU ARE
AWARE THAT WE ACTUALLY HAVE A
LOT OF USEFUL INFORMATION AT THE
NCI WEBSITE AND I URGE YOU TO
CONSULT THAT IF YOU WANT TO AND
IN ADDITION, THERE ALSO IS
INFORMATION ABOUT NCRA, FOR
EXAMPLE, JUNE'S PRESENTATIONS
ARE ALL ARCHIVED AT THE NCRA
WEBSITE CONNECTED TO THE NCI.
SO ANY OF THE NEW MEMBERS WHO
WANT TO SEE WHAT WAS PRESENTED
LAST TIME, YOU CAN GO THERE AND
SEE WHAT THOSE PRESENTATIONS
ARE.
THERE ARE SLIDES ON TWO
INITIATIVES.
ONE I APOLOGIZE, IT'S NOT
SUPPOSED TO BE AN ADVERTISEMENT
FOR MYSELF BUT REALLY FOR SIMON
SPRINGFIELD THE HEAD OF OUR
CENTER TO REDUCE CANCER HEALTH
DISPARITIES WHO IS LEGENDARY AND
LED THIS FOR 20 YEARS AND WE
HAVE A BLOG AGAIN AVAILABLE AT
THE NCI WEBSITE AND THE MOON
SHOT SCHOLARS.
THIS IS TO INCREASE THE
DIVERSITY OF EARLY STAGE
INVESTIGATORS FROM UNDER
REPRESENTED MINORITIES AND THIS
IS A PROGRAM WE'RE ALREADY
STARTING NOW AND WE HOPE TO HAVE
THE FIRST SET OF MOONSHOT
SCHOLARS IN FY23.
THOUGH LATER IN THE FISCAL YEAR
THOSE OF YOU WHO ARE KEEPING
TRACK, FY23 STARTS ON SATURDAY.
AND THIS IS THE TELEHEALTH
RESEARCH CENTERS OF EXCELLENCE.
WE ALREADY MADE AWARDS EARLIER
THIS MONTH TO FOUR ACADEMIC
INSTITUTIONS TO ESTABLISH
CENTERS OF EXCELLENCE TO CONDUCT
RESEARCH ON HOW TELEHEALTH CAN
CONTRIBUTE TO IMPROVE
CANCER-RELATED HEALTH CARE AND
ONCE AGAIN, YOU CAN GET MORE
INFORMATION AT THE NCI WEBSITE
AT THE CANCER MOONSHOT URL.
AND AS I MENTIONED LAST TIME,
INCREASING ENROLLMENT OF UNDER
REPRESENTED GROUPS AND NCI
TRIALS AND INCREASING ENROLLMENT
IN GENERAL IS GOING TO BE A
CENTERPIECE OF THE NEW PHASE OF
THE CANCER MOONSHOT AND HERE ARE
THREE OF THOSE GOALS.
WE WANT TO MIMIC THE AT-RISK
POPULATION FOR THE SPECIFIC
CANCER STUDY.
AND THIS IS NOT JUST A QUESTION
OF HAVING UNDER REPRESENTED
GROUPS IN THOSE POPULATIONS, BUT
ALSO HAVING PEOPLE WHO HAVE
CO-MORBIDITIES WHO FREQUENTLY
HAVE BEEN EXCLUDED FROM CLINICAL
TRIALS TO MAKE SURE THEY CAN BE
INVOLVED.
WE NEED TO HAVE A GREATER
INVESTMENT WITH COMMUNITY
ENGAGEMENT AND WE HAVE A PROGRAM
THAT WE STARTED FOR THIS BUT ONE
OF MANY TO COME.
AND THEN WE NEED MORE DIVERSITY
AMONG HEALTH CARE PROVIDERS.
WE HAVE NOT BEEN STANDING STILL
WHEN IT COMES MINORITY
ENROLLMENT AND THANKS TO THE
EFFORT OF DR. McCASKILL-STEVENS
WHO RUNS THE NCOR, IN THE LAST
20 YEARS WE'VE HAD A SUBSTANTIAL
INCREASE IN THE PERCENTAGE OF
ENROLLMENT TO NCI CLINICAL
TRIALS AND THAT INCLUDES THE
NATIONAL CLINICAL TRIALS NETWORK
ENROLLMENT AS WELL.
IT WENT FROM 14% DURING A
THREE-YEAR PERIOD AT THE
BEGINNING AT THE BEGINNING 2017
TO '19 TO 25% MINORITY
ENROLLMENT AND MOST THE INCREASE
IN BLACK AND AFRICAN AMERICAN
AND HISPANIC POPULATIONS.
AND THE DATA FOR 2020 AND 2021
DESPITE THE PANDEMIC, INDICATE
THE PERCENTAGE OF MINORITY
ENROLLMENT IF ANYTHING IS HIGHER
THAN 2017 TO 2019 PERIOD.
THIS IS SOMETHING ELSE WE'RE
DOING WHEN IT COMES TO THE
HEALTH DISPARITIES AND CLINICAL
TRIALS TO TRY TO INCREASE
DIVERSITY AND EQUITY AND
INCLUSION NOT JUST IN LATE-PHASE
TRIALS BUT EARLY-PHASE TRIALS
AND HERE'S A MEETING OPEN TO
EVERYONE THAT'S GOING TO BE
NOVEMBER 16th AND HOSTED BY THE
NCI EQUITY AND INCLUSION
PROGRAM.
THIS SLIDE REALLY TELLS YOU
ABOUT WHAT I CONSIDER TO BE THE
HOLISTIC ASPECT OF THE NCI
RESEARCH.
THIS PARTICULAR SLIDE IS HERE TO
HIGHLIGHT RO1 RESEARCH GRANT
AWARDS.
THINK ABOUT THIS AS GEARS AS THE
NCI FUNDING IS THE GEARS ON THE
LEFT WAS SHOWN ON THE RIGHT
IMPROVED OUTCOMES AND IT'S
REALLY IMPORTANT FOR US TO MAKE
SURE THAT ALL OF THOSE GEARS ARE
WELL OIL AND THERE IS NO SAND IN
EVEN ONE OF THEM BECAUSE IT CAN
SLOW DOWN OUR PROGRESS.
THIS IS TAKEN FROM THE ANNUAL
PLAN AND BUDGET AND DR. PALMIERI
WILL BE TALKING TO ME AND WILL
BE IN CHARGE OF THE ANNUAL PLAN
AND BUDGET PROPOSAL.
SHE'S IN AN EXCELLENT POSITION
TO TALK WITH YOU ABOUT IT.
AND THE ACTING DIRECTOR FOR
RESEARCH STRATEGY AND DOES AN
AMAZING JOB.
I'M SHOWING YOU THE BUDGET
ASPECT BECAUSE WE ARE PROPOSING
A SUBSTANTIAL INCREASE FOR FY24.
AND THAT'S TO BE ABLE TO
ESSENTIALLY GET THE MOON SHOT
STARTED THE RE-IGNITION OR
RE-IGNITING OF THE CANCER
MOONSHOT AS PRESIDENT BIDEN SAYS
AND TO MAKE SURE WE DO NOT
NEGLECT THE REGULAR BASE BUDGET
OF THE NCI WHICH IS SO IMPORTANT
FOR SO MANY DIFFERENT AREAS.
WE'RE VERY AMBITIOUS BUT THE
PRESIDENT IS VERY AMBITIOUS AND
IN ORDER TO TRY TO FULFILL HIS
VISION FOR ENDING CANCER AS WE
KNOW IT, WE THINK IT REQUIRES
THIS KRIEPD OF INVESTMENT.
ENDING CANCER AS WE KNOW IT IS
NOT JUST GOING TO BE DECREASING
MORTALITY RATES FROM CANCER BY
50% IN THE NEXT 50 YEARS BUT
NEED TO DO BETTER WITH THOSE
CANCERS WHERE THE OUTLOOK THUS
FAR IS NOT VERY GOOD.
A LOT OF VOWS BRAIN CANCERS AND
PANCREATIC AND OTHER CANCER
TYPES UNFORTUNATELY.
I SHOW THIS SLIDE IN SHUN AND
NOT THAT MUCH HAS HAPPENED AND
THE POINT OF THE SLIDE IS WE
NEED TO SEE WHAT THE FULL YEAR
APPROPRIATION WILL BE FOR FY23.
IT LOOKS LIKE CONGRESS IS GOING
TO PASS A CONTINUOUS RESOLUTION
SO WE WON'T HAVE A LAPSE IN
FUNDING AND BUDGET BUT THE
CONTINUING RESOLUTION WILL JUST
BE FOR CONTINUING THINGS AT THE
LEVEL OF FY22.
SENATOR BLUNTS HAS BEEN A
STAUNCH ADVOCATE FOR NIH
RESEARCH IN GENERAL AND THE NIH
AND NCI HAVE RECEIVED INCREASES
EACH YEAR.
HE'S NOT JUST A STRONG ADVOCATE
AND PART OF THE BIPARTISAN
SUPPORT FOR NIH IN GENERAL AND
NCI SPECIFICALLY AND WILL NO
LONGER BE IN THE SENATE BUT IT'S
UNLIKELY WE'LL GET A FULL YEAR
BUDGET BY DECEMBER BECAUSE
OTHERWISE SENATOR BLUNT WON'T BE
ABLE TO LEAVE HIS MARK ON THIS
AREA AND YOU'LL HERE MORE ABOUT
THE BUDGET.
LET ME STOP THERE AND REITERATE
THAT AND I THINK DR. BERTAGNOLLI
WILL BE TERRIFIC AND I'LL STILL
BE THE PRINCIPLE DEPUTY
DIRECTOR.
NCI IS TRYING TO MOVE FORWARD.
I THINK IT'S A VERY GOOD SIGN
THAT THE PRESIDENT IS
HIGHLIGHTING SOME OF OUR
PROGRAMS THAT WE ARE PRE POSING
FOR THE MOONSHOT AND I
PARTICULARLY PLEASED THAT
DR. YOUNG IS GOING TO BE ABLE TO
TALK WITH YOU THIS AFTERNOON SO
THAT YOU WILL REALLY GET
FIRST-HAND INFORMATION ABOUT THE
MOON SHOT FROM A LEADER AT OSTP.
I LOOK FORWARD TO YOUR COMMENTS
AND QUESTIONS, THANKS VERY MUCH.
>>THANK YOU, DR. LOWY.
THANK YOU FOR SHOWING US YOU'RE
NOT GOING TO BE GOING ANYWHERE
FAR.
WE CAN STILL TRACK YOU DOWN.
>>NOBODY ELSE WILL TAKE ME.
WOW, SO MANY EXCITING
INITIATIVES COMING THROUGH AND I
WAS SO PLEASED WHEN WE GOT THE
ANNUAL PLAN COPY TO REVIEW
BEFORE THE MEETING SHOWING THE
STATE WHERE THE HIGHER MORTALITY
IS AND THE UNDER SERVED
POPULATION BECAUSE I ALWAYS ASK
ABOUT IT.
I WAS PLEASED TO SEE THAT AS
PART OF THE ANNUAL PLAN.
>>ANNIE IS REFERRING TO THE
AREA OF PERSISTENT POVERTY AND
THAT IS ASSOCIATED WITH HIGHER
INCIDENTS AND MORTALITY FROM
CANCER AND I IMAGINE
DR. PALMIERI WILL DISCUSS THAT.
SORRY IF I INTERRUPTED.
>>AND I THINK OUR NEW MEMBERS
HAVE NO IDEA WHAT I'M TALKING
ABOUT BUT IT'S ON THE SECOND OR
THIRD PAGE.
IT'S VERY PROMINENT SO I
APPRECIATE SEEING THAT AND
THAT'S PART OF THE PLAN.
SO MY QUESTION I'LL SAVE MY MOON
SHOT QUESTION BUT YOU SAID YOU
MOTORCYCLE AT THE ACRR DISPARITY
SUMMIT AND WONDERING WHAT DO YOU
THINK AS ADVOCATES, WHAT AREA
NEEDS ATTENTION BECAUSE SO MUCH
NEEDS TO BE DONE, WHAT AREA CAN
WE SPECIFICALLY HELP BRING
ATTENTION TO IN TRYING TO MOVE
THE SCIENCE FORWARD IN SO MANY
WAYS THAT ARE HAPPENING AT NCI.
>>AT SOME LEVEL, I WOULD SAY
ALL OF THE BOF.
-- ABOVE.
I TEND TO AGREE WITH YOU THAT A
LOT OF EMPHASIS IS GIVEN TO
UNDER REPRESENTED MINORITYIES AD
PEOPLE THINK OF THE RACIAL AND
ETHNIC MINORITIES BUT THERE'S
DEMOGRAPHIC MINORITIES WHICH ARE
VERY IMPORTANT.
CONTINUING TO EMPHASIZE THAT IS
REALLY IMPORTANT.
THE TELEHEALTH INITIATIVE IS
SOMETHING WHERE WE'RE TRYING TO
BRING CANCER CARE TO THE PATIENT
RATHER THAN THE PATIENT TO
CANCER CARE SOME AREAS ARE
ESSENTIAL TO GO TO THE AREA
WHERE TO A TERTIARY CARE
FACILITY OR SOME OTHER FACILITY
BUT WHERE POSSIBLE WE'RE TRYING
TO CHANGE THINGS SO THAT PEOPLE
CAN START EITHER AT HOME OR
LOCALLY.
FOR EXAMPLE, ONE OF THE THINGS
WE'RE EXCITED ABOUT IS THE
MULTI-CANCER DETECTION TESTS.
IT'S REALLY IMPORTANT WE BE
INVOLVED BECAUSE TECHNOLOGY
DEVELOPMENT IS NOT INHERENT LY
GOING TO INCREASE GAPS, DECREASE
GAPS OR BE NEUTRAL.
BY THINK ING AING ABOUT THIS EA
IS GOING TO BE IMPORTANT BECAUSE
NCI IS PUTTING FRONT AND CENTER
NOT ONLY ARE THE MULTI-CANCER
DETECTION TESTS BE ABLE TO SAVE
LIVES BUT CAN IT BE DONE
EQUITABLY?
THOSE ARE TWO ISSUES WE'LL TRY
TO ADDRESS AT CLINICAL TRIALS.
>>I SEE NICOLE HAS A QUESTION.
>>YOU'RE MUTED.
>>I HAVE MY DOG BARKING IN THE
BACKGROUND.
I HOPE THAT'S NOT TOO
DISTRACTING.
I APPRECIATE THE PRESENTATION
AND APPRECIATE FROM THE CANCER
MOONSHOT PERSPECTIVE THERE'S A
FOCUS ON SCREENING, EARLY
DETECTION, MULTI-CANCER
DETECTION BECAUSE AS YOU KNOW
IT'S NOT AS FLASHY AS TREATMENT
AND SEEING OUTCOMES FROM
TREATMENT RESPONSES AND WE KNOW
ROUTINE SCREENING SAVES LIVES
AND GET TREATED AT AN EARLY
STAGE VERSUS WAITING FOR LATER
STAGE CANCERS AND THEN TRY TO
TREAT THEM AND WE KNOW THOSE
AREN'T GOING TO HAVE AS GOOD AS
OUTCOMES AND I APPRECIATE THAT
FOCUS.
I KNOW THAT WE'RE GOING TO BE
TALKING MORE ABOUT THE CANCER
MOON SHOT LATER BUT I WAS
CURIOUS IF THERE'S A FOCUS ON
METASTATIC CANCER BECAUSE WE
KNOW PATIENT HAVE POORER
OUTCOMES WITH METASTATIC
CANCERS.
>>LET ME HIGHLIGHT TWO AREAS.
ONE IS WE ARE PROPOSING TO
EXPAND THE PIPELINE OF NEW
DRUGS, OKAY.
WHEN WE SAY THAT, WE'RE TALKING
ABOUT PREVENTION SCREENING,
DIAGNOSIS AND TREATMENT BUT A
LOT OF IT WOULD BE IN THE AREA
OF CANCER TREATMENT.
WHAT MANY PEOPLE DON'T REALIZE
IS THAT NCI SUPPORTED
INVESTIGATORS ARE DEEPLY
INVOLVED IN DEVELOPING NEW
TREATMENTS AND NEW TREATMENT
APPROACHES.
FOR EXAMPLE, 10 YEARS AGO THE
RAS-ONCOGENES IMPLICATED IN MANY
HAVE US CANCER THOUGHT TO BE
UNDRUGGABLE.
THROUGH RESEARCH BY
NCI-SUPPORTED INVESTIGATORS IN
2021, THE FIRST RAS SPECIFIC
INHIBITOR DRUG WAS APPROVED BY
THE FDA.
SO THIS IS THE KIND OF THING
THAT NCI SUPPORTED INVESTIGATORS
REALLY ARE AT THE FOREFRONT OF
DOING.
A SECOND AREA IS YOU MAY HAVE
HEARD OF THE MATCH TRIAL WHICH
WE STARTED DURING THE PREVIOUS
CANCER MOONSHOT AND WE SEE THE
DEVELOPMENT OF COMBINATIONS OF
TREATMENT TARGETED AS WELL AS
IMMUNOTHERAPY AS BEING AN
IMPORTANT POTENTIAL AREA FOR
MAJOR ADVANCEMENT.
THOSE ARE TWO AREAS THAT ARE
RELATED TO YOUR QUESTION.
>>THANK YOU FOR SHARING THOSE
UPDATES.
I HAVE A QUESTION ABOUT THE
RESEARCH PROGRAM FOR TRYING TO
INCREASE REPRESENTATION --
>>THE MOONSHOT SCHOLARS
PROGRAM.
>>YES.
WONDERING IF THERE'S INFORMATION
AVAILABLE WE CAN SHARE ABOUT
THAT PROGRAM AND -- YEAH,
IT'S -- THERE ARE TWO EASY
PIECES OF INFORMATION BOTH AT
THE NCI WEBSITE ONE AT THE MOON
SHOT SCHOLARS THERE'S A SEPARATE
AREA FOR THAT AND THEN WE DID A
BLOG ABOUT IT.
YOU CAN GET INFORMATION BOTH
PLACES.
>>AND WHILE I HAVE YOU, ARE YOU
INCLUDING PSYCHOSOCIAL
RESEARCHERS?
>>THERE IS NO RESTRICTION ON
THE KIND OF RESEARCH THEY BE
INVOLVED IN BUT ASK THE RESEARCH
BE CANCER RELEVANT.
>>PERFECT.
THANK YOU.
>>JACKIE, WE CAN SEND YOU THE
INFORMATION TO THE ENTIRE BOARD
AFTER THE MEETING TO MAKE IT
EASIER.
>>THANKS, AMY.
>>DO WE HAVE ANY OTHER
QUESTIONS?
>>I WASN'T TRYING TO SAY DON'T
ASK ME QUESTIONS ABOUT THE
MOONSHOT, IF YOU THINK ANY THAT
WOULD BE MORE APPROPRIATE FOR
ME, THAT'S JUST FINE.
>>THIS IS THE ONE TO PUT OUT
THERE AND I THINK I'VE ASKED
THIS BEFORE IS WE KEEP SAYING
THE PHRASE END CANCER AS WE KNOW
IT AND I WONDER IF THAT'S BEEN
CLEARLY DEFINED BECAUSE I THINK
PEOPLE ARE THINKING OF IT IN
DIFFERENT WAYS.
-- TO ME, IT HAS TWO PARTS TO
IT.
AND THE FIRST IS TO MAKE THE
EXPERIENCE BETTER FOR PATIENTS.
SO IN OTHER WORDS TO MAKE SURE
THE CANCER CARE EXPERIENCE IS
SOMETHING THAT IS AS POSITIVE AN
INTERACTION AS POSSIBLE AND HIS
GOES FROM PREVENTION AND
SCREENING AND DIAGNOSIS AND I
DON'T MEAN FOR JUST PEOPLE WHO
HAVE CANCER BUT THE SECOND PART
IS IF WE DON'T MAKE PROGRESS ON
THE CANCER WHERE'S WE HAVE HAD
LIMITED PROGRESS UP TO NOW AND
ENDING CANCER FOR ALL.
>>WHEN I FIRST HEARD THE
PHRASE, WHAT CAME TO MY MIND ARE
THE PEOPLE WHO MIGHT NOT
NECESSARILY BE CURED OF THEIR
CANCERS.
AND GETTING IN THE MAINSTREAM AS
A SUCCESS, WHICH I THINK IT IS,
AND VERSUS A CONTROL WOULD BE
EXCITING.
>>AND FOR LUNG ADENO CARCINOMA
THE TREATMENT HAS IMPROVED THE
OUTLOOK FOR THOSE PATIENTS IN A
SUBSTANTIAL WAY.
>>THAT'S BEAUTIFUL.
THANK YOU SO MUCH.
>>THIS IS AMAZING.
A GOVERNMENT PRESENTATION THAT
ACTUALLY FINISHES ON TIME.
>>AND WE KNOW YOU HAVE MORE
IMPORTANT THINGS --
>>NO.
>>OTHER IMPORTANT THINGS.
MY BAD.
OTHER IMPORTANT THINGS.
>> I WENT -- CAN'T WAIT TO HE
SEE ALL OF YOU IN THE FUTURE.
THANKS A LOT.
>>THANK YOU FOR SPENDING TIME
WITH US.
WE'LL FIND A WAY TO BRING YOU
BACK IN TOO.
AMY, DO YOU WANT TO GO AHEAD AND
INTRODUCE THE NEXT PERSON OR IS
THAT ON ME?
>>WE CAN DO IT TOGETHER.
THANKS EVERYBODY.
SO TO PIGGY BACK ON DR. LOWY'S
PRESENTATION AND REFERENCED OUR
DEAR COLLEAGUE, DR. PALMIERI AND
SHE'LL TALK ABOUT SOME OF THE
SCIENCE IN THE PAST AND DR. LOWY
REFLECTED A BIT ON THAT WITHIN
HIS PRESENTATION BUT HE WAS
ORIGINALLY GOING TO HAVE MORE OF
AN OPPORTUNITY TO SHARE THAT
SCIENCE AND WAS NOT ABLE TO
TODAY DUE TO SCHEDULING ISSUES
AND DIANE IS HERE TO WALK YOU
THROUGH SOME OF THE SCIENTIFIC
AREAS THAT ARE HIGHLIGHTED IN
THE ANNUAL PLAN AND SORT OF WHY
AND HOW THEY WERE SELECTED.
SO I'LL TURN IT OVER TO YOU FOR
THAT AND WE AGAIN APPRECIATE YOU
BEING HERE.
>>DOUG IS ALWAYS A HARD ACT TO
FOLLOW AND GAVE ME SUCH A
BILLING I HOPE I CAN LIVE UP TO
IT.
I'LL TALK MORE ABOUT THE
HIGHLIGHTED SCIENTIFIC TOPICS IN
THIS YEAR'S ANNUAL PLAN AND
BACKGROUND ON THE PLAN IN
GENERAL AND HOW WE PUT IT
TOGETHER.
>>IT'S TO INCREASE THE
ANTICIPATION OF YOUR
PRESENTATION.
>>SURE, MORE PRESSURE.
I UNDERSTAND YOU RECEIVED A COPY
OF THE PLAN AHEAD OF THE MEETING
SO THAT'S GREAT.
YOU CAN FIND THE PLAN AT
CANCER.gov.
THE PLAN IS FULLY INTEGRATED
INTO CANCER.gov.
IT'S SOMETHING WE DID ABOUT TWO
YEARS AGO AND IT'S INTEGRATED
INTO CANCER.gov AND ENCOMPASSES
ALL OF NCI RESEARCH PORTFOLIO
AND HAS A SUMMARY DOCUMENT WE
CALL THE AT-A-GLANCE YOU CAN
DOWNLOAD AND DISTRIBUTE AS WELL
AS THE INTEGRATED WEBSITE.
WE RELEASE THE ANNUAL PLAN EVERY
SEPTEMBER.
WE TEND TO REFER TO THE ENTIRE
DOCUMENT AS THE PLAN BUT THERE
ARE REALLY TWO COMPONENTS.
THE PLAN COMPONENT AND THE
PROFESSIONAL JUDGMENT BUDGET
WHICH DOUG SHOWED ON HIS SLIDE
THE BUDGET TABLE.
SO THE PLAN CONTENT SERVED AS
NCI'S DYNAMIC STRATEGIC PLAN AND
GIVES A CHANCE TO DISCUSS
PRIORITIES AND DISCUSS
SCIENTIFIC PRIORITIES ON AN
ANNUAL BASIS.
WE ALSO HIGHLIGHT PATIENT AND
RESEARCHER STORIES IN THE ANNUAL
PLAN EACH YEAR AS WELL AS CANCER
ADVANCES.
PROFESSIONAL BUDGET IS AN
ASPIRATIONAL BUDGET
COMMUNICATION AND MEANT TO
CONVEY THE OPTIMAL FUND NEEDED
TO CONTINUE TO MAKE PROGRESS
AGAINST CANCER.
AND WE PUT THE BUDGET AND THE
PLAN OUT TWO YEARS IN ADVANCE.
AS DOUG NOTED WE'RE ABOUT TO END
FISCAL YEAR 2022 ON FRIDAY AS IT
ENDS AT THE END OF SEPTEMBER AND
START FISCAL YEAR 2023 IN THE
GOVERNMENT.
WE PUT OUT EARLIER THIS MONTH
THE ANNUAL PLAN AND BUDGET
PROPOSAL FOR FISCAL YEAR 2024.
WE DO THIS SO THAT WE HOPE THE
PRESIDENT WILL CONSIDER THE FY24
PROFESSIONAL JUDGMENT BUDGET AS
HE STARTS HIS PROGRESS FOR THE
BUDGET PROPOSAL FOR CONGRESS
COMING OUT IN THE SPRING AND
WILL FOLLOW THE APPROPRIATION
HEARINGS.
THE AT-A-GLANCE DOCUMENT
CONTAINS THE BUDGET TABLE AND
MESSAGE FROM THE NCI DIRECTOR
AND OTHER KEY SUMMARIZED
INFORMATION.
THAT WHOLE PACKAGE IS OUR ANNUAL
PLAN AND BUDGET PROPOSAL EACH
YEAR.
FOR THE PAST SEVERAL YEARS WE'VE
BEEN HIGHLIGHTING THREE TO FOUR
SCIENTIFIC OPPORTUNITIES IN
GREATER DEPTH OPPOSED TO LISTING
POTENTIAL OPPORTUNITIES
THROUGHOUT THE PLAN.
THE PLAN CONVEYS THE ENTIRETY OF
NCI'S RESEARCH PORTFOLIO SO IT
PUTS OUT A VISION FOR EACH AREA
OF CANCER RESEARCH ALONG WITH
SUPPORTING CANCER TRAINING FOR
THE CANCER RESEARCH WORKFORCE
AND SUSTAINING CRITICAL
INFRASTRUCTURE SUCH AS THE
CANCER CENTERS AND THE DATA
COMMONS THAT ARE ALL NECESSARY
TO CONDUCT THE RESEARCH.
I'M GOING TO TALK A LITTLE MORE
IN DEPTH ABOUT THE SCIENCE OR
SCIENTIFIC OPPORTUNITIES.
THESE TOPICS ARE CHOSEN EACH
YEAR BY NCI LEADERSHIP AND
CONSIDER A NUMBER OF THINGS
INCLUDING EMERGING AREAS OF
SCIENCE, AREAS OF CANCER
RESEARCH WHERE INCREASED
INVESTMENT OR ATTENTION COULD
SPUR MORE ADVANCES AND OTHER
THINGS PERTINENT TO THE TIME.
STAFF FROM ACROSS THE NCI
CONTRIBUTE THEIR EXPERTISE TO
THE DEVELOPMENT OF THE CONTENT
AND HELP IDENTIFYING THE AREAS
FOR INVESTMENT AND OUTLINING NCI
PROGRAMS THAT ARE IMPORTANT TO
THE TOPIC AND HIGHLIGHTING
RECENT ADVANCEMENT ON RESEARCH
THAT CAN BE CAPITALIZED ON AREAS
OF OPPORTUNITY.
THIS YEAR THE FOUR SCIENTIFIC
AREAS ARE ASYMPTOMATIC TESTING
AND SELF-THERAPY AND POVERTY AND
UNDRUGGABLE CANCER TARGETS.
I'LL GO THROUGH THESE FOUR WITH
MORE DETAIL.
I'M GOING START WITH PERSISTENT
POVERTY AND A DIDN'T KNOW THAT
WAS ANNIE'S FAVORITE TOPIC
BEFORE I PUT THE SLIDES IN THE
ORDER.
WE'RE GOING TO KICK IT OFF BY
TALKING ABOUT THE PROBLEM OF
PERSISTENT POVERTY IN CANCER.
AS THE SLIDE STATES IN BIG BOLD
LETTER, CANCER DEATH RATES ARE
12% HIGHER IN COUNTIES WITH
PERSISTENT POVERTY THAN OTHER
COUNTIES AND NOTES 85% OF THESE
COUNTIES WITH PERSISTENT POVERTY
ARE IN RURAL AREAS OF THE UNITED
STATES.
WHEN YOU CONSIDER THESE TWO
STATISTICS IT'S IMPORTANT TO
UNDERSTAND THE DEFINITION OF
PERSISTENT POVERTY AS WELL.
PERSISTENT POVERTY IS WHERE 20%
OF THE POPULATION OR MORE SO A
FIFTH OF THE POPULATION IN A
GIVEN AREA HAVE LIVED BELOW THE
POVERTY LEVEL FOR THE PAST 30
YEARS.
THIS IS A CHRONIC
MULTI-GENERATIONAL PROBLEM AND
WILL REQUIRE POPULATION-LEVEL
SOLUTIONS TO MAKE A DIFFERENCE.
NCI IS FUNDING RESEARCH TO
UNDERSTAND HOW THE FACTORS
ASSOCIATED WITH PERSISTENT
POVERTY, THINGS SUCH AS
INCREASED EXPOSURE TO
CANCER-CAUSING AGENTS IN THESE
AREAS, STRESS AND LACK OF ACCESS
TO HEALTH CARE AMONG OTHER
FACTORS INTERSECT TO AFFECT
CANCER OUTCOMES FOR PEOPLE
LIVING IN THESE AREAS.
WE'RE WORKING TO UNDERSTAND THE
PROBLEM AND TEST INTERVENTIONS
ACROSS THE INDIVIDUALS,
COMMUNITY AND POPULATION TO
CHANGE THE OUTCOME FOR PEOPLE IN
THESE AREAS.
WE'RE EXPLORING TELEHEALTH AND
SUPPORTING RESEARCH PARTNERSHIPS
BETWEEN NCI-DESIGNATED CENTERS
AND COMMUNITY HEALTH PROVIDERS
IN THESE AREAS TO DETERMINE HOW
TO BEST DELIVER INTERVENTIONS TO
AREAS OF PERSISTENT POVERTY.
YOU DON'T THINK I HAVE TO TELL
THIS GROUP WE HAVE EFFECTIVE
SCREENING TEST FOR A FEW TYPES
OF CANCERS AND DON'T HAVE TO
TELL YOU MULTI-CANCER DETECTION
TESTING HAS GENERATING A LOT OF
BUZZ IN RECENT YEAR AS WITH
BIOPSY TESTING OR THE IDEA CAN
DETECT MULTIPLE CANCERS FROM A
SING AT BLOOD DRAW.
THROUGH RESEARCH AND DEVELOPMENT
THIS TECHNOLOGY HAS NOW REACHED
A STATE WHERE SEVERAL ASSAYS
HAVE BEEN DEVELOPED ARE READY
FOR LARGE-SCALE CLINICAL TESTING
TO DETERMINE THEIR BENEFITS AND
FULLY UNDERSTAND THEIR HARMS AND
DOUG ALLUDED TO THIS A LITTLE.
WHAT DID WE MEAN?
WE DON'T KNOW IF THE TESTS WILL
REDUCE DEATH FROM CANCER AND
IT'S LARGE-SCALE TESTING AND
TAKES TIME.
WE ALSO DON'T KNOW IF IT WILL
LEAD TO DIAGNOSTIC PROCEDURE
WILL CAUSE UNDUE HARMS TO
OTHERWISE HEALTHY INDIVIDUALS.
WE DON'T KNOW HOW THEY'LL
COMPARE TO THE EFFECTIVE
SCREENING TESTS FOR COMMON
CANCER, WILL THEY BE BETTER AND
CHANGE PRACTICE IN THOSE AREAS?
WE ALSO AS DOUG ALLUDED TO AND
TALKED PASSIONATELY ABOUT, WE
DON'T KNOW THE TESTS WILL
BENEFIT ALL POPULATIONS EQUALLY.
WE WON'T KNOW THAT UNLESS WE
TEST THEM AT ALL POPULATIONS
EQUALLY.
IF WE DETERMINE THEY WILL WORK
ACROSS POPULATIONS AND
SITUATIONS, THEN WE MUST ENSURE
THEY DO WORK IN THESE
POPULATIONS AND THAT THEY ARE
DELIVERED AND ACCESSIBLE TO THE
POPULATIONS.
NCI LAUNCHED RECENTLY A CANCER
SCREENING RESEARCH NETWORK THIS
WILL BUILD ON NCI'S CLINICAL
TRIAL INFRASTRUCTURE AND
NETWORKS AND ANSWER QUESTIONS
ABOUT MULTI-CANCER EARLY
DETECTION TESTING.
BY RIGOROUSLY EVALUATE THESE
TESTS AND ENSURING THE BENEFITS
OUTWEIGH THE POTENTIAL HARMS, WE
MAY BE ABLE TO TAKE IMPORTANT
STEPS FORWARD TOWARD ENDING
CANCER AS WE KNOW IT TODAY AS
PREVIOUSLY DISCUSSED.
THE THIRD TOPIC IS CELLULAR
THERAPY.
THIS IS AN IMMUNOPERSONALIZED
THERAPY USING A PERSON'S OWN
IMMUNE CELLS TO TREAT CANCER.
PEOPLE WHO RESPOND TO THIS
TREATMENT OFTEN HAVE AMAZING AND
DURABLE RESPONSES YET NOT ALL
PEOPLE RESPOND AS WE DON'T HAVE
CELL THERAPY OPTIONS FOR MOST
CANCERS.
90% OF ALL CANCER DIAGNOSES ARE
SOLID TUMORS IN ORGANS NOT BLOOD
LIKE LYMPHOMAS.
THERE'S NO CELL THERAPIES FOR
ANY SOLID TUMORS AT THIS POINT.
MORE BASIC RESEARCH IS REALLY
NEEDED TO DEVELOP MORE CELL
THERAPIES TO TREAT MORE CANCER
PATIENTS.
IT'S THE KIND OF BASIC IMM
IMMUNOLOGY SUPPORTED THAT LED TO
CHECKPOINT INHIBITERS NOW
APPROVED MORE IN CANCERS AND
ANOTHER BARRIER IS IT'S
EXPENSIVE AND DIFFICULT TO
PROVIDE AT A SCALE TO TREAT
LARGE NUMBER OF PATIENTS AT A
TIME.
RESEARCH FUNDED THROUGH THE
MOONSHOT LED TO ADVANCES IN CELL
THERAPY FOR ADULTS AND PEDIATRIC
PATIENTS.
TO BUILD ON THE PROGRESS IN THE
NEXT PHASE, NCI RECENTLY
LAUNCHED THE CELLULAR THERAPY
NETWORK FOR TESTING OF CELLULAR
THERAPIES FOR SOLID TUMORS.
THINGS THAT HAVE BEEN DEVELOPED
AND NOW READY TO TEST.
THE CANCER DRUG RESEARCH OFFICE
CELL THERAPY MANUFACTURING TO
RESEARCHERS ACROSS THE UNITED
STATES.
INVESTMENTS WILL HELP BRING MORE
CELL THERAPY OPTION TO MORE
POPULATIONS IN THE FUTURE.
THE FINAL TOPIC IS UNDRUGGABLE
CANCER TARGETS.
THIS IS AN EXCITING AREA OF
CANCER RESEARCH WHERE LONG-TERM
INVESTMENTS ARE REALLY STARTING
TO PAY OFF.
AS DOUG MENTIONED, LAST YEAR THE
FDA APPROVED THE FIRST TARGETED
THERAPY FOR THE MUTANT FORM OF
THE K-RAS ONCOGENE FOR LUNG
CANCER.
IT'S A FAMILY OF CANCER-CAUSING
GENES MUTATING IN UP TO 30% OF
ALL HUMAN CANCERS.
THIS WAS A CELEBRATED MILESTONE
FOR THE DRUG DEVELOPMENT FIELD
BECAUSE RAS WAS LONG THOUGHT OF
AS ONE OF THE ULTIMATE
UNDRUGGABLE CANCER TARGETS.
THIS BREAKTHROUGH WAS MADE
POSSIBLE BY ADVANCES IN A NUMBER
OF FIELDS.
THINGS LIKE MEDICINAL CHEMISTRY,
COMPUTATIONAL BIOLOGY AND I
CAN'T STRESS ENOUGH THE
IMPORTANCE OF THE COMPUTATIONAL
FIELD AND BEING ABLE TO SPEED
DRUG DEVELOPMENT PROCESSES AND
ADVANCES IN MICRO SCSCOPY AND
IMAGING TECHNIQUES TO LOOK AT
THE PROTEINS AND DRUGS
INTERACTING.
THESE ADVANCES COUPLE WITH MORE
KNOWLEDGE WITH CANCER BIOLOGY
TODAY THAN WE HAVE HAD MAKE IT
BOBBLE TO ENVISION A FUTURE
WHERE NO CANCER TARGET ARE
CONSIDERED UNDRUGGABLE.
AND THERE'S AN INHERITED
SYNDROME THAT CAUSES TUMORS TO
FORM IN MULTIPLE PARTS OF THE
BODY AND UNTIL RECENTLY THE ONLY
TREATMENT OPTION WAS SURGERY TO
REMOVE THE TUMORS WHEN POSSIBLE.
THE VHL GENE WHEN MUTATED IS
RESPONSIBLE FOR THE DISEASE AND
AGAIN THIS WAS LONG CONSIDERED
AN UNDRUGGABLE TARGET.
NCI SUPPORTED RESEARCH LED TO
THE DEVELOPMENT OF A TARGETED
THERAPY FOR SOME TYPES OF VHL
ASSOCIATED TUMORS AND THE FDA
APPROVAL LAST AUGUST.
THIS DRUG IN JUSTIN'S OWN WORDS
CHANGED HIS LIFE.
I ENCOURAGE YOU TO READ HIS FULL
STORY IN THE PLAN.
IT'S QUITE REMARKABLE.
AND PLEASE, READ MORE ABOUT EACH
OF THESE SCIENTIFIC TOPICS IN
THE PLAN.
IN CLOSING, I JUST WANT TO IT
RATE WHAT I SAID IN THE
BEGINNING -- ITERATE WHAT I SAID
ALONG WITH THE PLANS THERE'S THE
NCI BROAD RESEARCH PORTFOLIO
THAT SPANS THE BASIC BIOLOGY
RESEARCH TO DEVELOPING AND
TESTING TREATMENTS TO DELIVERING
THESE TREATMENTS AND THE
BENEFITS OF CANCER RESEARCH TO
ALL THROUGH PUBLIC HEALTH
INTERVENTIONS.
WITH THAT I'LL CLOSE AND TAKE
QUESTIONS.
>>DOES ANYONE HAVE ANY
QUESTIONS?
SO I WILL START WITH A QUICKIE
BEFORE ANYONE HAS THEIR HANDS
UP.
AT OUR LAST MEETING WHEN WE
HEARD FROM DR. CASSEL, THEY WERE
CALLED EARLY CANCER EARLY
DETECTION TEST AND NOW SEEING
OTHER NAME.
IS NACD THE NEW NMCD.
>>I'D GO WITH MCDT, MULTICANCER
DETECTION TEST.
>>WE LOVE ACRONYMS.
>>WHEN THERE'S A BROAD
CONSENSUS ON JUST LET US KNOW SO
WE CAN STAY UP TO DATE.
>>GO WITH MULTICANCER DETECTION
TESTING.
PART IS WHERE ARE WE TESTING AND
WHAT TEST ARE WE TEST ING?
ARE WE TESTING IN ASYMPTOMATIC
POPULATION OR LATER STAGE OR FOR
EARLY DETECTION.
THERE'S A LOT OF DIFFERENT
MULTIPLES OF FACTORS THAT GO
INTO THAT.
BOIL IT DOWN TO MCDs.
>>AND FROM ONE OF THE CANCERS
AND I THINK WE HAVE OTHERS
REPRESENTED THAT DON'T HAVE A
SCREENING TEST WE KEEP OUR EYE
ON THIS, I THINK IF WE'RE JUST
DETECTING CANCER, IF THERE'S A
TUMOR ALREADY OR NOT I LIKE
EARLY STAGE SHIFT WHICH MAY OR
MAY NOT INCREASE -- DECREASE
MORTALITY.
I LIKE THE AMCD BECAUSE THE
SCREENING TEST FROM IS FOR
ASYMPTOMATIC HEALTHY POPULATION
SO THAT FITS IF WE'RE GOING TO
TIE IT INTO SCREENING GIST FROM
MY PERSPECTIVE.
IF I GET TO VOTE, THAT'S WHAT
I'M GOING VOTE FOR, CLEARLY.
>>IN ITS BEST POSSIBLE FORM
THAT'S WHAT IT WILL DO.
>>AND I GUESS I'M REALLY
EXCITED ABOUT THE CELL THERAPY.
WE'VE ALL SEEN SOME OF THESE
DURABLE DURABLE RESPONSES AND
MAKING THEM MORE AVAILABLE
ESPECIALLY IF THERE'S A
SPECIALIZED COMPONENT TO IT
SEEMS IT COULD REACH THE RARE
CANCERS WHERE RESEARCH IS
LACKING.
WHAT'S THE BIGGEST CHALLENGE IN
THIS AREA TO MAKE IT MORE
WIDESPREAD.
>>WE HAVE A CELL THERAPY EXPERT
ON THE CALL AND WE HAVE THE
CHIEF OF OUR ONCOLOGY BRANCH HAS
JOINED US.
I WANT TO TURN IT OVER TO HIM
AND LET YOU GET THE BEST
INFORMATION.
>>HI, MARK, THANKS FOR JOINING.
>>THANK YOU FOR ALLOWING ME TO
JOIN.
THERE'S A NUMBER OF BARRIERS AND
CLEARLY FOCUSSING ON SOLID
TUMORS IS A VERY DIFFERENT BEAST
TO ATTACK FOR A NUMBER OF
BIOLOGICAL REASONS.
WE FOCUSSED ON SOLID TUMORS IN
OUR EFFORTS IN ADULT AND
PEDIATRIC PATIENTS TO PROPOSE
TRIALS IN THESE AREAS.
LOOKING AT PERSONALIZED
MUTATIONS CAN BE DONE IN A
NUMBER OF PROTEINS PARTICULARLY
IF ONE USES T CELL RECEPTORS
OPPOSED TO THE ANTIBIOTIC
RECEPTORS USED IN THE CLASSIC
CAR T CELLS BECAUSE THE TCRs,
THE T CELL RECEPTOR ALLOWS FOR
IDENTIFICATION OF MUTATED
PROTEINS EXPRESSED ON MCH CLASS
ANTIGENS AND LOOKING AT THE
MICROENVIRONMENT IS A CRITICAL
AREA IN SOLID TUMOR THAT NEEDS
TO BE ADDRESSED.
AND FINALLY THE DEVELOPMENT OF
RESISTANT PATHWAYS BOTH
ENDOGENOUS AND AREQUIRED --
ACQUIRED RESISTANCE.
WE'RE TRYING TO ADDRESS THIS IN
THE RFAs OUT THERE.
>>THANK YOU.
I'M SO EXCITED YOU WERE HERE TO
ANSWER THE QUESTION.
IT'S LIKE A SURPRISE GUEST.
>>I WANT TO ADD TO -- I'M
EXCITE ABOUT THE CELL THERAPY
DIRECTION AS WELL AND ESPECIALLY
BECAUSE WE WERE TALKING ABOUT
DURABLE RESPONSES AND WE KNOW
THAT TUMORS ARE SMART AND THEY
CAN -- THEY'RE HETEROGENEOUS AND
CAN CHANGE OVER TIME AND THE
FACT THAT IT CAN BE DONE IN A
WAY TO TARGET THE TUMOR CAN HELP
RATHER THAN A TARGETED MUTATION.
I SEE MORE PROMISE THAN MAYBE
THE OTHER DRUG DEVELOPMENT
AREAS.
>>ONE CAN INCLUDE THE
PREVENTION IN TERMS OF
DEVELOPMENT OF VACCINES AND
STRATEGIES AND TARGETS AND
UNDERSTANDING SHARED MUTUAL
MUTATIONS ACROSS DIFFERENT TUMOR
TYPES ARE REALLY CRITICAL.
VERY IMPORTANT IN PEDIATRIC
CANCERS BECAUSE THEY'RE NOT
USUALLY BROADLY MUTATED.
THEY'RE USUALLY DRIVEN BY OTHER
FACTORS AND ARE PARTICULAR
CHALLENGES.
THANK YOU FOR THE COMMENT.
>>THANKS TO MARK AND
DR. PALMIERI FOR THE GRET
CONVERSATION THIS MORNING AND
AFTERNOON.
WOULDN'T BE MORE THRILLED ABOUT
THE FOUR INITIATIVES THAT LIFTED
OFF THE PAGE WITH THE
EXPLANATION YOU GAVE US AND
GREAT POTENTIAL.
YOU MENTIONED FREDRIK'S LAB
WHICH HAS GOTTEN SOME
NOTARIETY.
>>ARE THERE ELIMINATIONS IN
WHAT WE CAN ENGAGE THEM TO DO?
>>YES.
>>WE WORK WITH THE FREDRIKS
LACK AND IT DOES INTERACT ON
VIRUSES AND WE HAVE THE ATTO
LEVERAGE THE MAJORITY OF THE
FOCUS AND POWER TO CONCENTRATE
ON CANCER RESEARCH AND WE
COLLABORATE ON PROJECTS AND
THERE ARE DEFINITELY THINGS THE
FREDERICK NATIONAL LAB HAS THE
ABILITY TO DO AT A DIFFERENT
SCALE THAT NCI RESEARCHERS CAN
DO.
IT'S ABOUT LEVERAGING BOTH
POTENTIALS TO GET THE FULL
BENEFIT OF BOTH THE NCI AND THE
NATIONAL LABORATORY.
>>THAT'S GREAT.
THANK YOU VERY MUCH.
>>DID YOU HAVE A QUESTION?
>>I WANTED TO BRING UP THE
TOPIC OF CANCER VACCINES AS IT
WAS MENTIONED IN THE ORIGINAL
MOONSHOT ADDRESS BUT HAVEN'T
HEARD MUCH TALK ABOUT THAT.
I WONDER IF THERE'S ANYTHING TO
SPEAK OF IN THAT SPACE.
>>THAT'S A GREAT QUESTION.
I CAN RUN THAT DOWN FOR YOU AND
MAY BE A QUESTION FOR DR. YOUNG
IN THE AFTERNOON SESSION BECAUSE
IT'S COMING TO YOU FROM OSDP.
THOSE ARE TWO AREAS TO
FOLLOW-UP.
THANK YOU.
>>ARE THERE ANY OTHER
QUESTIONS?
I'M GOING TO BRING IT BACK --
>>I'M ONE OF THE NEW PEOPLE
HERE AND HAVE BEEN INTRIGUED BY
THE IDEA OF THE MULTI-CANCER
EARLY DETECTION PROGRAM OR
THERAPY.
PROSTATE CANCER IS ONE OF THE
CANCER'S THAT HAS A REASONABLY
EFFECTIVE EARLY DETECTION
STRATEGY AND WHAT'S MORE
IMPORTANT OF IDENTIFYING THE
CANCER WHILE IT'S STILL
TREATABLE.
I WONDER WHAT YOUR VISION IS FOR
HOW MULTI-CANCER EARLY DETECTION
APPROACH WOULD WORK IN
CONJUNCTION WITH EXISTING EARLY
DETECTIONS FOR PROSTATE CANCER
AND OTHER CANCERS.
WOULD ONE REPLACE THE OTHER OR
BE BLENDED OR USED IN SEQUENCE
AND I KNOW THIS IS STILL SORT OF
EARLY IN OUR THINKING ABOUT HOW
THIS MIGHT WORK BUT CURIOUS YOUR
THOUGHTS ON THAT.
>>I THINK THOSE ARE GREAT
QUESTIONS.
I THINK YOU'RE RIGHT ON TARGET
FOR A NEW PERSON FOR THE KINDS
OF QUESTIONS TO BE ASKING.
WE REALLY DON'T KNOW HOW THEY'LL
WORK WITH EXISTING SCREENING
TESTS.
I WOULD SAY IN A PERFECT WORLD
IF WE SHOW VIGOROUS CLINICAL
TRIALS AND TESTING, THESE EARLY
DETECTION TESTS, THESE BLOOD
TESTS PERFORM BEST THAN COMMON
SCREENING TEST.
WE WOULD WORK TO REPLACE THE
COMMON SCREENING TEST BUT IT
WOULD BE A LONG TIME AND IN MOST
CASES I WOULD SAY THERE'LL BE
DONE IN CONJUNCTION WITH ONE
ANOTHER FOR A LONG TIME INTO THE
FUTURE UNTIL WE CAN ASSURE THE
NEW TEST ACCURATELY CAN REPLACE
THE OLD TESTS.
AND SO IT'S A LOT OF TESTING ON
BOTH OF THOSE.
WHEN YOU LOOK AT SOMETHING LIKE
CANCER SCREENING, YOU'RE
STARTING WITH AN ASYMPTOMATIC OR
PRESUMABLY HEALTHY POPULATION
AND TRYING TO DETECT CANCER,
WHICH ACTUALLY IS A RARE EVENT
IN PEOPLE THOUGH IT SEEMS VERY
PROMINENT IN SOCIETY WHEN YOU
THINK ABOUT IT BY THE NUMBERS
AND IT TAKES QUITE A WHILE TO
DETERMINE IF SCREENING TEST
ACCURATE AND PRECISE AND WHEN
WE TEST THE MULTI-CANCER
DETECTION TESTS AND SEE WHAT WE
THINK ABOUT THOSE AND
INTEGRATING THEM INTO SCREENING
GUIDELINES AND COMPARE THEM TO
THE EXISTING TESTS WHERE WE DO
HAVE EFFECTIVE CANCER
SCREENINGS.
>>THANK YOU.
>>THAT WAS A GREAT QUESTION AND
WE HAVE DR. CASSEL FROM THE
DEPARTMENT WHO HEADS THE
DEPARTMENT OF PREVENTION ON WITH
US LAST MEETING AND GIVE A
PRESENTATION DEDICATED TO THE
MULTI-CANCER EARLY DETECTION
TESTS.
AND ALSO THE PLAN TO DO A
CLINICAL TRIAL TRIAL AT NCI
WHICH YOU MIGHT FIND INTERESTING
AND WE'RE TRYING TO GET
DR. CASSEL BACK ONCE THAT HAS
BEEN ONGOING FOR A WHILE TO GET
A LITTLE BIT OF A REPORT BACK OR
EVEN AS IT'S STARTING TO GEAR UP
AND IN EARLY STAGES AND
SOMETHING THEY'RE STARTING TO
TALK ABOUT AND BECAUSE IT'S A
NEW TECHNOLOGY WE'RE ALSO
LOOKING HOW TO VALIDATE THAT IS
SOMETHING THAT PEOPLE ARE IT'S
LIKE PEOPLE ARE COMING UP WITH
IN REAL TIME AND IT'S VERY
INTERESTING.
>>I WATCHED THE RECORDING OF
THE PRESENTATION AND IT WAS VERY
GOOD.
>>WE MAY BE ABLE TO TWIST HIS
ARM TO COME TALK TO US AGAIN.
DO WE HAVE ANY OTHER QUESTIONS?
>>THANK YOU FOR BREAKING DOWN
THE ANNUAL PLAN FOR US AND THE
EXCITING AREAS OF FOCUS AND
WE'RE LOOKING FORWARD TO HEARING
MORE AND FINGERS CROSSED THE
BUDGETS GET APPROVED AND ALL THE
SONG AND DANCE HAPPENS.
WE'RE EXCITED.
THANK YOU FOR THE HARD WORK.
>>MY PLEASURE.
>>THANK YOU, DIANE.
THREW FOR THE TERRIFIC
QUESTIONS.
IT'S A HELPFUL FOR KEEPING THE
SCIENCE MOVING AND MAKING SURE
WE'RE MOVING IN A DIRECTION THAT
BENEFITS PATIENTS.
THAT'S PROBABLY A GOOD SEGUE FOR
OUR NEXT PRESENTATION.
I CAN TURN IT OVER TO YOU TO
INTRODUCE OUR NEXT PRESENTER AND
I CAN TAG TEAM IT WITH YOU
>>I'M SO EXCITED THAT ANDREA
DENICOFF IS HERE TO TELL US
ABOUT THE COVID-19 IN CANCER
STUDY AND IF YOU PREFER ACRONYMS
NCCAPS THE FASTEST CLINICAL
TRIAL TO GO FROM CONCEPT TO
OPENING EVER.
I HOPE THAT PART IS INCLUDED IN
THE PRESENTATION BUT ANDDREE --
ANDREA THANK YOU FOR COMING TO
REPORT OUT ON THAT WE'RE LOOKING
FORWARD TO HEARING.
>>THANK YOU FOR THE OPPORTUNITY
TO COME SPEAK TO YOU AND TALK TO
YOU.
THANKS, ANNIE FOR THE ACRONYM.
WE LIKE TO USE THEM INSTEAD OF
USING THE NCI COVID-19 IN CANCER
PATIENTS STUDY.
THE STUDY SPECIFICALLY FOR
PEOPLE WITH CANCER ON ACTIVE
TREATMENT AND WHO HAVE COVID-19.
WHAT I WANTED TO DISCUSS TODAY
WAS A LITTLE BIT OF THE
BACKGROUND AND ANNIE, SINCE YOU
MENTIONED YOU WANTED TO HEAR THE
BEGINNING, I CAN ADD THAT IN
THERE.
I THOUGHT YOU'D BE INTERESTED IN
HEARING THE ROLE THE ADVOCATES
PLAYED IN NNCAPS AND THEY HELPED
RECRUIT ADVOCATES.
AND I'LL PRESENT EARLY FINDINGS
AND WHAT WE HOPE TO LEARN.
MAYBE END OF MARCH EARLY APRIL I
GOT A CALL FROM DR. DORSHELL
SAYING WE NEED TO GET A STUDY UP
AND RUNNING AS FAST AS WE KCAN O
SEE WHAT COVID IS DOING TO OUR
PATIENTS AND NEED TO GET IT UP
AND RUNNING AS FAST AS WE CAN
AND WE SAID WILL YOU JOIN US IN
THIS EFFORT TO ESSENTIALLY WORK
NON STOP UNTIL WE GET A STUDY
GOING AND THAT INCLUDED TWO
PATIENT ADVOCATES THAT
VOLUNTEERED OR ACCEPTED
VOLUNTEERING FOR THIS WE WORKED
TIRELESSLY FOR FIVE OR SIX WEEKS
AND DR. DORSHELL LIKES TO SAY WE
GOT IT IN FIVE WEEKS AND I THINK
IT WAS BETWEEN FIVE AND SIX
WEEKS WE GOT THE PROTOCOL
WRITTEN THROUGH THE CENTRAL IRB.
OF COURSE WE DID ASK IF WE CAN
BEAT THE LINE FOR OTHER
PROTOCOLS IN REVIEW FOR TIMELY
BECAUSE WE WANTED TO CAPTURE
WHAT WAS HAPPENING IN THE
COUNTRY SO FAST.
AND WE HAD EXPERTS WHO HELPED
PARTICIPATE AND THE CO-P.I.s AT
VANDERBILT AND OTHER AND I
SHOULD ACKNOWLEDGE THEM BECA
BECAUSE'S AN OBSERVATIONAL STUDY
AND FOLLOWING PATIENTS ON STUDY
UP TO TWO YEARS AND THE PURPOSE
WAS TO CHARACTERIZE FACTORS THAT
WERE ASSOCIATED WITH SHORT AND
LONG-TERM OUTCOMES OF COVID-19
BECAUSE WHEN WE STARTED THE
STUDY IT WAS STILL SO NEW WE
WEREN'T SURE WHAT WAS HAPPENING
IN PEOPLE OUTCANCER LET ALONE
PEOPLE WITH CANCER BUT THERE
WERE EARLY DATA COMING OUT OF
CHINA THAT CANCER PATIENTS
ESPECIALLY WITH LUNG CANCER AND
LEUKEMIA SEEMED TO DO MUCH
WORSE.
WE WANTED TO LOOK AT THAT AND
TRACK OTHERS FOR OTHER PRE
EXISTING MORBIDITIES AND EIGHTH
OTHER DEMOGRAPHIC FACTORS AND
THINGS LIKE AGE, RACE, EVEN
THINGS SUCH AS SMOKING.
AND ANY CANCER MODIFICATIONS
THAT NEEDED TO BE MADE BECAUSE
OF COVID-19.
THIS IS THE SCHEMA OF HOW WE
ENROLLED PATIENTS TO THE STUDY.
IF SOMEONE WITH BEING TESTED FOR
THE SARS COV2 VIRUS THEY CAN
ENTER THE STUDY AND SOMETIMES IT
TOOK SEVERAL DAYS TO GET THE
TEST RESULTS BACK AND DIDN'T
WANT TO LOSE THE OPPORTUNITY TO
ENROLL SOMEONE AND HAD A
SCREENING STEP THEY COULD GO ON
UNTIL THEY WERE WAITING FOR
THEIR RESULTS.
THE RESULT CAME BACK NEGATIVE
THEY WOULD GO OFF STUDY BUT IF
IT TESTED POSITIVE WE COULD
START THE DATA COLLECTION.
SOME PATIENTS ALSO MIGHT HAVE
STARTED IF THEY WERE
HOSPITALIZED FOR ANY REASON
INCLUDING COVID-19 AND COULD
START THE STUDY IF THEY WERE IN
PATIENT AND THE PLAN WAS TO TRY
TO RECRUIT PATIENTS AND FOLLOW
THEM FOR TWO YEARS TO FOLLOW
THEIR OUTCOMES.
SO THE STUDY PLAN BECAUSE IT'S
AN OBSERVATIONAL LONGITUDINAL
STUDY MOSTLY TO COLLECT DATA,
COLLECT SCANS AND COLLECT
RESEARCH SPECIMENS AND I'M
SORRY, I ALSO FORGOT TO PUT ON
HERE -- I GUESS IT'S THERE UNDER
COLLECT DATA WE ARE COLLECTING
QUALITY OF LIFE DATA.
AND LOTS OF DIFFERENT
DEMOGRAPHIC FACTORS PREEXISTING
COMORBIDITIES, COLLECTING
IMAGING SCANS.
THERE WAS AN INTEREST IN WILL
THE SCANS PICK UP SOMETHING
UNUSUAL WITH COVID-19 IN CANCER
PATIENTS AND ALSO IT'S ONE OF
THE ONLY STUDIES PROSPECTIVELY
COLLECTING BLOOD RESEARCH
SPECIMEN TO LOOK AT DIFFERENT
FACTORS ASSOCIATED WITH SEVERE
DISEASE.
NCI'S DIVISION OF CANCER
EPIDEMIOLOGY AND GENETICS WILL
DO GENOMIC-WIDE ASSOCIATION
STUDIES FOR PATIENTS WHO
SUBMITTED BLOOD TESTS AND WE'RE
ALSO LOOKING AT DIFFERENT IMMUNE
RESPONSES AND TRAJECTORY OF
IMMUNE RESPONSES AND ADDED A
VACCINE SUB STUDY FOR THOSE
INTERESTED THAT WOULD ALLOW US
TO DRAW ADDITIONAL BLOOD TO
FOLLOW THEM FOR ANTIBIOTICS AND
SEROLOGY STUDIES AFTER INFECTION
OF SARS COV2.
WE HAD TWO ADVOCATES THAT AGREED
TO WORK WITH US AND WE DID HAVE
THESE MEETINGS SOMETIMES TWICE
OR THREE TIMES A WEEK.
AND THEY SERVED AS MEMBERS OF
OUR STUDY WORKING GROUP FROM THE
VERY FIRST MEETING THEY JOINED.
THEY WERE QUITE VOCAL IN
PROVIDING INPUT AND STUDY
OBJECTIVES IN THE PROTOCOL AND
PEOPLE REALLY LISTENED TO THEM.
AND THEY ALSO ADDITIONALLY WHEN
ASKED THEY ACTUALLY REVIEWED AND
PROVIDED INPUT ON THE INFORMED
CONSENT AND COMMUNICATION
MATERIALS.
SOME GOOD FEEDBACK ON THAT.
I CAN REMEMBER OF THEM DOING
WONDERFUL CHANGES IN THEM AND
THEY ALSO WE ASKED IF THEY
WANTED TO SERVE ON ADDITIONAL
FOR EACH OF THE DIFFERENT
CORRELATIVE SUB STUDY GROUPS WE
ASKED FOR VOLUNTEERS AND WERE
ACTIVE IN THE QUALITY OF LIFE
SUBSTUDY COMPONENT AS WELL.
WE'RE HAVING ANOTHER WORKING
GROUP MEETING COMING UP SOON
WHERE WE'LL PRESENT TO THE GROUP
DIFFERENT THINGS WE WANT TO
INCLUDE IN OUR FIRST LARGE
PAPER.
THEY'VE BEEN PART OF THE STUDY
TEAM AND IF YOU ASKED THEM MY
HUNCH IS THEY FELT INCLUDED
BECAUSE NO ONE WAS AN EXPERT ON
SARS COV2 WHEN WE STARTED THIS
SO TO HAVE THE PATIENT'S VOICE
PRESENT ON THIS WAS REALLY KEY.
I WANT TO THANK AMY FOR ALSO
QUICKLY REACHING OUT AND
THROWING OUT WHO IS WILLING TO
GIVE UP THEIR TIME TO DO THIS.
THAT WAS REALLY HELPFUL.
WE CLOSE THE STUDY THIS YEAR.
WE HAVE A SMALL NUMBER OF
PATIENTS WHO COMPLETED THEIR TWO
YEARS OF FOLLOW-UP AND SO FAR
SUBMITTED ABSTRACT FOR THE
ASCO2021 AND HAVE IN PATIENT AND
OUT-PATIENT ABSTRACT.
UNFORTUNATELY, THEY WERE
POSTERS.
THEY WEREN'T PODIUM
PRESENTATIONS.
WE WERE LIKE, WOW, WHY ISN'T
THAT -- BUT I THINK BECAUSE THE
WAY COVID IT HIT COUNTRY SO FAST
I THINK THE EDUCATIONAL PLANNING
FOR THAT MEETING WAS WELL
UNDERWAY.
WE HAD ABSTRACTS FOR THAT
MEETING AND SUBMITTED AN
ABSTRACT FOR THE AMERICAN
SOCIETY OF HEMATOLOGY OR ASH
MEETING WHERE WE'RE PRESENTING
AND HOPEFULLY PRESENTING RESULTS
OF OUR COAGULATION STUDIES AND
THAT LOOKED AT ISSUES WITH
CLOTTING AND COVID-19 AND
CANCER.
AND LOOKING AT VACCINE SEVERITY
ANALYSIS AS WELL.
WE DID SCREEN OVER 2,000
PATIENTS FOR THE STUDY.
WE WENT ON TO STUDY OVER 1800
AND YOU CAN SEE THE MAP ACROSS
THE COUNTRY TO GET
REPRESENTATION FROM PRETTY MUCH
ALL OVER THE COUNTRY.
WE DID HAVE EVERY STATE IN THE
COUNTRY AS WELL AS D.C. AND
PUERTO RICO HAD A STUDY SITE
OPEN.
WE WERE HAPPY TO GET SITES OPEN
EVERYWHERE ACROSS THE COUNTRY
AND HAD 171 CHILDREN ENROLL IN
THE STUDY.
AND THE COVE NET AT THE BOTTOM
WITH 84 IS ACTUALLY A SMALLER
SUBSET OF PEDIATRIC PATIENTS
THAT WAS ANOTHER SUB STUDY
WORKING TOGETHER WITH NCI'S
CANCER CENTER LOOKING AT
CHILDREN SURVIVORS OF CANCER AND
COVID.
AND ANOTHER CORRELATIVE SUBSTUDY
LOOKING AT ONCE PATIENT ON THE
STUDY AND EVENTUALLY GETTING
VACCINATED TO LOOK AT HOW THEIR
VACCINES WERE TO STUDY THE
UPTAKE IN THE ANTIBODIES FOR
THEM.
WE HAD AT LEAST 70 PATIENTS OR
MORE CONTRIBUTE AT LEAST ONE
SPECIMEN FOR THAT STUDY AS WELL.
AND WE DID GET ROBUST ACCRUAL
WENT WITH THE WAYS OF THE COVID
PANDEMIC IN THE COUNTRY.
NOW I'LL PRESENT THE PRELIMINARY
RESULTS SINCE WE'VE ONLY
PUBLISHED THIS INFORMATION SO
FAR THIS IS WHAT I HAVE
AVAILABLE TO SHOW YOU.
YOU CAN SEE AT THE TIME OF THE
PUBLICATION WE ONLY INCLUDE THE
PATIENTS WE HAD COMPLETE DATA
SETS FOR AND I KNOW FROM OUR
SITES AND MAYBE IT'S BEEN A
TOPIC YOU'VE ALL DISCUSSED IS
WHAT'S BEEN HAPPENING AROUND THE
COUNTRY IN TERMS OF THE GREAT
RESIGNATION ALSO UNFORTUNATELY
HAPPENED WITH OUR SITES AND
THEY'RE LOSING CLINICAL RESEARCH
PROFESSIONALS.
SOME OF OUR SITES SAID BECAUSE
YOU SAW THERE WERE -- WE DIDN'T
ENROLL A PATIENT IN EVERY STATE
ACROSS THE COUNTRY WHILE WE DID
HAVE SITES OPEN THAT SOME OF IT
WAS JUST DUE TO STAFFING ISSUES.
AND SO TO GET COMPLETE DATA SETS
WE HAD 780 ADULT PATIENTS WITH
COMPLETE DATA SETS AT THE TIME
OF THIS ABSTRACT AND ABOUT 50
PEDIATRIC PATIENTS.
YOU CAN SEE FOR THE ADULT
PATIENTS THE BAR GRAPH SHOWS
CANCERS THAT WE -- PATIENTS WITH
CANCERS ENROLLED AND YOU CAN SEE
BREAST CANCER WAS THE MOST
COMMON CANCER ENROLLED AND THE
ORANGE AND GREEN STAND FOR
WHETHER THE CANCER WAS
METASTATIC DISEASE OR NOT
METASTATIC.
ME PURPLE IN TERMS OF MULTIPLE
MYELOMA AND LYMPHOMA ARE NOT
STAGED THE WAY THEY TYPICALLY
ARE AND THE MAJORITY ARE FOR
BREAST AND LUNG CANCER -- LUNG
CANCER CAME AFTER BREAST AND
G.I. REPRESENTS MANY CANCERS
FROM COLON TO ESOPHAGEAL TO
PANCREATIC.
WE HAD THE PRIMARILY BREAST,
LUNG AND THE OTHER VERY HIGH
NUMBER WAS ALSO MULTIPLE MYELOMA
AND IN PEDIATRICS THE MAJORITY
WERE CHILDREN WITH LEUKEMIA AND
THAT'S THE MOST COMMON CANCER IN
KIDS AS WELL.
AND WE SAW MORE THAN 50% OF
ADULTS WITH CANCER WERE EITHER
CURRENT OR FORMER SMOKERS.
MANY OF THEM HAD CARDIAC AND
PULMONARY COMORBIDITIES.
20% ON SOME TYPE OF
ANTICOAGULATION WHEN THEY
DEVELOPED COVID.
WE HAD A NUMBER OF PATIENT WITH
DIABETES AND OTHER COMORBIDITIES
AS YOU CAN HE SEE -- AS YOU CAN
SEE AND LESS THAN 1% HAD A
PREGNANT PATIENT ON THE STUDY.
AND YOU CAN SEE FATIGUE WAS THE
GREATEST PRESENTATION AND I'M
SURE EVERYONE BY NOW IS WELL
FAMILIAR WITH ALL THE COVID-19
SYMPTOMS BEING SO PREVALENT IN
THE NEWS THAT THESE SYMPTOMS
PRETTY MUCH MIRROR WHAT'S BEEN
HAPPENING IN THE GENERAL PUBLIC
AS WELL.
YOU CAN SEE THE LINE GRAPH NEXT
TO THE TABLE THAT SHOWED HOW
THEY INITIALLY STARTED WITH
THEIR HIGHER PERCENTAGE OF
SYMPTOMS BUT GRADUALLY GO DOWN
OVER A THREE-MONTH PERIOD.
IN TERMS OF THE OUTCOMES OF THE
OUTCOME OF THE INITIAL COHORT WE
LOOKED AT FOR THE ASCO ABSTRACT,
ABOUT 800 PATIENTS ALL-CAUSE
MORTALITY WAS JUST SHY OF 10%.
A THIRD DIED OF THEIR CANCER AND
LITTLE LESS THAN A THIRD DIED OF
OTHER CAUSE AND A THIRD FROM
COVID.
AND ABOUT LITTLE LESS THAN 130
PATIENT HOSPITALIZED FOR
COVID-19 AND AT LEAST 31 HAD
MULTIPLE COVID-19-RELATED
HOSPITAL STAYS AND CHILDREN WITH
CANCER THERE WAS ONE DEATH FROM
MALIGNANCY BUT NO DEATHS FROM
COVID-19.
SOME OF THE FUTURE DIRECTIONS
WE'RE LOOKING AT NOW IS WE'RE
DOING A MAJOR DATA CLEANING
EFFORT.
WE HAVE ABOUT 250 SITES ACROSS
THE COUNTRY THAT HAVE LARGE
NUMBERS OF PATIENTS THEY
ENROLLED AND SO WE'RE WORK WITH
THEM TO MAKE SURE WE GET -- WE
HAVE NO DELINQUENCY IN THE DATA
BECAUSE WE HAVE HAD TO WORK WITH
OUR SITES CAREFULLY AS THEY LOST
STAFF AND WORK WITH THEM AS THEY
GET NEW STAFF UP AND RUNNING AND
LEARN THE STUDY.
WE'RE IN THE PROCESS RIGHT NOW
OF LOOKING AT MANY OF OUR
CORRELATIVE STUDIES.
WE HAVE AN ABSTRACT SUBMITTING
TO THE AMERICAN SITE OF
HEMATOLOGY ON THE COAGULATION
STUDIES WE'VE DONE AND LOOKING
AT IMMUNE CELL PHENOTYPING AND
CYTOKINE PROFILES AND THOSE
STUDIES WILL TELL US HOW MUCH
THE IMMUNE SYSTEM AS WE EITHER
IMPACTED OR POTENTIALLY EITHER
HELPED PATIENT OR DIDN'T HELP
THEM WITH THE COVID-19 AND THE
SEROLOGY AND NEUTRALIZING
ANTIBODY STUDIES LOOKING AT
PATIENTS WHO ARE VACCINATED AND
THEIR DEVELOPING ANTIBODIES TO
COVID-19.
THOSE WILL BE INTERESTING
STUDIES THAT WE'LL EVENTUALLY
PRESENT AND THE QUALITY OF LIFE
LOOKS AT PATIENT REPORTED
OUTCOMES IN SYMPTOMS FROM
FATIGUE TO SOME OF THE PHYSICAL
SYMPTOMS, COUGH AND ALSO WE HAVE
A NEURO-COG, TO LOOK FOR
COGNITIVE IMPAIRMENT IN PATIENTS
AND PEOPLE SAYING NOT ONLY DO
THEY HAVE CHEMO BRAIN BUT NOW
COVID FOG.
NOT THAT WE'LL BE ABLE TO TEASE
EACH OUT BUT AT LEAST LOOKING TO
SEE THE IMPACT OF THOSE ON
PATIENT-REPORTED QUALITY OF LIFE
AND THAT WILL BE A LONG-TERM
ASSESSMENT PATIENT WHO'S AGREE
TO HAVE THEIR QUALITY OF LIFE
SURVEYS COMPLETED ARE THERE TO
REPORT THEIR SYMPTOMS OVER A
TWO-YEAR PERIOD.
THAT WILL BE NICE TO HAVE
LONGITUDINAL DATA ON THAT AND
OUR SPECIALTY PEDIATRIC COHORT
WILL PROBABLY PUBLISH THEIR
FINDINGS SEPARATELY.
IT'S A SMALLER STUDY BUT
OBSERVATIONAL AND IT WILL BE
IMPORTANT TO REPORT AND THEN THE
IMAGING FINDINGS WILL ALSO
PROBABLY BE A SEPARATE PAPER AS
WELL.
THERE'S LOTS OF DIFFERENT GROUPS
IN PROCESS THAT ARE PULLING DATA
TOGETHER SO WE'LL HAVE MUCH MORE
TO REPORT ONCE THIS COMES OUT
BUT I THOUGHT AT LEAST YOU CAN
HAVE AN UNDERSTANDING OF WHERE
THE STUDY IS NOW.
I AM AWARE DR. SHARPLESS HAS
COME TO YOU BEFORE AND PRESENT
THE STUDY BUT I UNDERSTAND
THERE'S NEW MEMBERS THAT HAVE
JOINED AND HAPPY TO ANSWER ANY
QUESTIONS HAVE IF THERE ARE ANY
ABOUT THIS.
>>I CAN'T LET EVERYONE KNOW
YOU'RE THE HEAD OF THE CLINICAL
TRIALS NETWORK FOR NCTN.
GIVE -- FORGIVE ME FOR THAT.
WE WERE EXCITED TO HEAR HOW
QUICKLY THIS CAME TOGETHER AND
ONE OF THE PATIENT ADVOCATES
FROM THE STEERING COMMITTEE ALSO
PRESENTED FROM THE ADVOCATE
PERSPECTIVE.
I DON'T WANT TO MENTION ANY
OTHER NAMES BECAUSE I DON'T KNOW
WHO THE SECOND ADVOCATE IS AND I
DON'T KNOW WHAT WE'RE FREE TO
MENTION HERE BUT WE HAD OUR EYE
ON IT AND JUST BEEN IN AWE AT
HOW RAPIDLY THIS CAME TOGETHER
AND AGAIN ADVOCATES WERE
INCLUDED IN EVERYTHING.
IT WAS SO MUCH IMPORTANT WORK
AND I'M EXCITED ABOUT THE
PEDIATRIC PATIENTS INCLUDED AS
WELL AND EXCITED TO LEARN FROM
THEIR EXPERIENCE.
ONE OF THE QUESTIONS I HAD WAS
SEEING HOW THE SYSTEMS TAPERED
OFF.
WAS THERE DIFFICULTY IN TRYING
TO PARS OUT WHETHER THE SYMPTOMS
WERE FROM THE COVID ITSELF OR
FROM A METASTATIC CANCER WHICH
MAY HAVE SIMILAR SYMPTOMS IF IT
ME T METASTASIZED TO THE LUNGS?
>>PATIENTS WITH LUNG CANCER
OFTEN HAVE SHORTNESS OF BREATH
AND WE'LL HAVE TO REPORT THE
DATA AND THE DATA IS THE DATA
AND YOU CAN LOOK FOR INCREASES
IN SYMPTOMS WITH COVID AND
PEOPLE WILL HAVE TO TAKE IT FOR
WHAT IT'S WORTH BECAUSE WE WON'T
BE ABLE TO REALLY TEASE THAT
OUT.
>>I'M ALSO VERY EXCITED ABOUT
THE VACCINATION STUDIES AND ONE
THING WITH THE VACCINES AN
BOOSTERS AND EVERYTHING THAT'S
COME OUT PEOPLE ARE LESS
FEARLESS OF DEATH AND
HOSPITALIZATION EVEN IF THEY
HAVE CANCER BUT WE'RE STILL
HEARING PEOPLE ARE AFRAID OF
LONG COVID AND NOT KNOWING HOW
PEOPLE WILL GET IT AND HOW LONG
IT WILL LAST AND HOW
DEBILITATING IT WILL BE.
I'M EXCITED TO SEE THAT'S
INCLUDED IN THE FUTURE
DIRECTION.
DOES ANYONE ELSE HAVE ANY
QUESTIONS OR COMMENTS?
>>IF I CAN ASK, YOU MENTIONED
AS PART OF THE PROBLEM WITH
ENROLL
ENROLLING AND LOOKING AT THE
COMMUNITIES I'M ENGRAINED WITH
OFTEN, I'M WONDERING IF YOU
COLLECTED DATA AS FAR AS
PATIENTS REFUSING TO ENROLL IN
THE STUDY WITH THEIR PERCEPTIONS
OR FEELINGS TOWARDS COVID-19 AND
IF THAT WAS TAKEN INTO ACCOUNT.
>>WHEN WE ASKED SITES THAT
WASN'T AN ISSUE.
THE MAJORITY OF PATIENTS WERE
HAPPY TO ENROLL.
WE DID ASK FOR A LOT OF SYMPTOM
DATA INITIALLY WHEN YOU WENT ON
STUDY YOU HAD TO REPORT YOUR
SYMPTOMS INITIALLY AND THEN TWO
WEEKS AND THEN ONE MONTH THERE
WERE SOME PATIENT WHO'S I THINK
WE DID HERE SOME PATIENTS WERE
TIRED OF REPORTING THEIR
SYMPTOMS AFTER BEING ON A BIT
AND WANTED TO COME OFF THE
STUDY.
THAT WAS A LITTLE DISAPPOINTING
BUT I GUESS IF YOU'RE SICK WITH
CANCER, YOU'RE ON TREATMENT AND
YOU'VE GOT COVID, MAYBE YOU'RE
TIRED AND DIDN'T HEAR PEOPLE
WERE AGAINST THE STUDY AND THE
MAIN THING THEY HAD TO DO WAS
REPORT THEIR SYMPTOMS AND YOU
CAN EVEN DO IT FROM HOME.
YOU DIDN'T HAVE TO COME TO
CLINIC FOR THE STUDY.
>>THAT WAS A GREAT QUESTION.
THANK YOU FOR ASKING.
DO WE HAVE ANY OTHER QUESTIONS?
ARE WE GOING TO GO ON BREAK
EARLY?
WELL, ANDREA, THANK YOU AGAIN SO
MUCH FOR REPORTING THIS OUT TO
US TODAY AND ALL THIS WORK AND
JUST I'M STILL AMAZED HOW
QUICKLY THIS CAME TOGETHER WE
DIDN'T KNOW ANYTHING.
WE APPRECIATE YOUR INPUT
>>IT WAS A HUGE TEAM EFFORT.
I'M ONE MEMBER OF A BIG TEAM AND
THE COMMITMENT OF EVERYBODY HAD
BECAUSE OF THE SERIOUSNESS OF
THE PANDEMIC WAS REALLY
SOMETHING.
WE RECRUITED AN ICU DOCTOR FROM
SEATTLE WHO WAS AN EXPERT IN
INFECTIOUS DISEASE AND HE WOULD
GET ON THE PHONE WITH US ON
CALLS AT DIFFERENT TIMES OF THE
DAY AND I REMEMBER LISTENING TO
NPR ONE DAY AND HEARD HIM BEING
INTERVIEWED BY NPR AND A FEW
MINUTES LATER HE WAS ON OUR CALL
AND I THOUGHT WHAT A COMMITTED
PERSON, HE'S WORKING AROUND THE
CLOCK.
I GIVE THAT AS A TIDBIT AS TO
THE AMOUNT OF COMMITMENT EVEN
OUR INVITED EXPERTS FROM AROUND
THE COUNTRY AND THAT INCLUDED
OUR PATIENT ADVOCATES THAT
JOINED THE EFFORT.
IT WOULDN'T HAVE HAPPENED IF IT
WEREN'T FOR EVERYBODY DROPPING
EVERYTHING AND DOING THIS.
IT SPEAKS TO THE COMMITMENT
EVERYBODY HAS WHEN THEY WANT TO
DO SOMETHING AND THE TIME OF
NEED THEY COME TOGETHER.
I FEEL REALLY FORTUNATE TO BE
PART OF SUCH A STRONG TEAM
EFFORT.
>>AGAIN, THANK YOU VERY MUCH
AND THANK YOUR TEAM AND WE HOPE
WE'RE LOOKING FORWARD TO HEARING
ABOUT THE EXPANSION AND FUTURE
DIRECTIONS WHEN WE HEAR BACK AND
WHO DO WE TALK TO AT ASCO TO SAY
THAT WAS NOT COOL?
>>I WAS LIKE THAT'S A PROBLEM.
>>THAT'S ALL RIGHT.
WE SAW OTHER COVID PAPERS WERE
ALSO POSTERS.
WE DIDN'T FEEL LIKE IT WAS
DIRECTED AT US.
IT WAS JUST THEIR GENERAL
ORGANIZATION OF THEIR MEETING.
THEY WEREN'T USED TO HAVING A
COVID SECTION THAT CAME ON ALL
OF A SUDDEN.
>>THANK YOU, EVERYONE.
IT'S BREAK TIME AND BECAUSE
WE'RE GETTING OFF A LITTLE EARLY
IF WE CAN BE BACK AT 1:55.
TURN OFF YOUR SCREEN AND
MICROPHONE.
WE'LL SEE YOU BACK AT 1:55.
THANKS.
>>THANKS TO ALL OF YOU FOR ALL
YOU DO.
>> MY COLLEAGUE, HOLLY, HAS
JOINED US WHO IS NEXT ON OUR
AGENDA.
THANK YOU, AS ALWAYS, HOLLY.
ANNIE, I'LL TURN IT TO YOU TO
INTRODUCE HOLLY.
>>THANK YOU EVERYONE FOR COMING
BACK PROMPTLY.
I'M EXCITED THAT OUR NEXT ITEM
OF BUSINESS IS THE BUDGET AND
LEGISLATIVE UPDATE AND WE HAVE
MS. HOLLY GIBBONS FROM THE NCI
OFFICE OF GOVERNMENT AND
CONGRESSIONAL RELATIONS TO GIVE
THAT UPDATE.
>>HI, EVERYONE.
THANK SO MUCH AND MY COLLEAGUE,
MAUREEN AND I ALWAYS APPRECIATE
THE OPPORTUNITY TO ATTEND AND
SHARE UPDATE IT'S TIMELY WHEN
THE MEETING IS DAYS FROM THE END
OF THE FISCAL YEAR.
A QUICK OVERVIEW OF WHAT WE'LL
COVER TODAY.
WE'LL SHARE AN UPDATE ON FY23
PRECIPITATIONS AS DR. LOWY
MENTIONED THE NEGOTIATIONS OVER
C.R. THIS WEEK AND A FEW ITEMS
THAT MAY BE CATCHING A RIDE OR
NOT ON THE CONTINUING
RESOLUTION.
AND IT WILL INCLUDE A STATUS
UPDATE ON ARPA-H PROPOSALS AND
FURTHER ESTABLISH THE NEW AGENCY
AND MAUREEN WILL PROVIDE UPDATES
ON OTHER RECENTLY ENACTED AND
LIKELY SOON TO BE ENACTED
LEGISLATION.
AND WE'LL SHARE A RECAP OF A FEW
RECENT EVENTS.
YOU'LL SEE THERE'S A TABLE SUM
ARRIZE -- SUMMARIZING OUR LEVELS
AND I'LL GET STARTED AND
HOPEFULLY WE CAN GET THE SLIDES
UP AFTERWARDS.
YOU'LL SEE THE SENATE PROPOSAL
PROPOSE A $290 MILLION INCREASE
FOR NCI AND THE HOUSE PROPOSED A
DIFFERENT AMOUNT FOR FY22.
FOR NIH THE SENATE PROPOSED A $3
BILLION INCREASE AND THE HOUSE
$2.5 BILLION INCREASE FOR
ARPA-H.
THE SENATE PROPOSED FUNDING AT
$1 BILLION AND THE HOUSE
PROPOSED AN INCREASE OF $1.75
BILLION.
I DO WANT TO MAKE IT CLEAR THAT
NEITHER THE HOUSE NOR THE SENATE
PROPOSALS FOR FY23 ARE
BIPARTISAN.
THERE'S STILL SIGNIFICANT
AGREEMENTS ON OVER ALL FUNDING
LEVELS AND WHAT THEY CALL PARITY
AND THAT LATTER BUDGET IS WHERE
OUR FUNDING COMES FROM.
WHILE BOTH THE HOUSE AND SENATE
PROPOSALS PRIMARILY REFLECT THE
PRIORITIES OF THE MAJORITY, THE
DEMOCRATS, AND WHILE BIPARTISAN
SUPPORT IS STILL REALLY STRONG,
NEITHER HAS THE SUPPORT OF THE
MINORITY.
AND SO IN THE HOUSE, THE BILL
DID PASS OUT OF COMMITTEE ALONG
PARTY LINES HOWEVER, THE SENATE
DID NOT HOLD COMMITTEE VOTES
THIS YEAR.
THE SENATE COMMITTEE POSTED
THEIR BILL PUBLICLY ON THE
WEBSITE BUT IT WASN'T CONSIDERED
A FULL COMMITTEE AND
SUBCOMMITTEE LEVEL.
THE PROPOSALS ARE A STARTING
POINT FOR NEGOTIATIONS AND
PARTICULARLY SINCE NEITHER IS
THE PRODUCT OF BIPARTISAN
AGREEMENT, IT MAKES IT VERY
UNCLEAR WHERE OUR FINAL
APPROPRIATION WILL LAND.
THERE'S SEVERAL POLICY IRISH --
ISSUES AND THE FOCUS IS ON
CONTINUING RESOLUTION PROVIDING
LEVELS THROUGH SEPTEMBER 16.
IT INCLUDES EMERGENCY AID FOR
UKRAINE HOWEVER, DOES NOT
INCLUDE EMERGENCY FUNDS FOR
COVID AND MONKEY POX RESPONSE.
I WANTED TO SHOW WHERE WE ARE IN
THE PROCESS AND WE'RE ONLY
MIDWAY AND WE HOPE THE
APPROPRIATION HAPPENS IN
DECEMBER AND NOT FURTHER IN THE
NEW YEAR.
AS I MENTIONED, THE IMMEDIATE
PRIORITY IS THE C.R.
IT'S MOVING FORWARD HOWEVER,
THERE HAS BEEN SOME CONTENTION.
WE'RE IN A BETTER PLACE TODAY
THAN YESTERDAY AND I WON'T TWO
IN THE WEEDS BUT IN CASE SOME
FOLKS HAVE NOTICE THE POLITICAL
COVERAGE OF CONGRESS IN THE
BUDGET PROCESS IN GENERAL YOU
MAY HAVE HEARD AN EARLIER ROUND
OF DEAL MAKING THREATENED TO
HOLD UP THE PROCESS OF FUNDING
THE DEPOSIT.
I'LL LEAVE THE DETAILS OF THE
INFLATION REDUCTION ACT BUT I
WANT TO MENTION IN ORDER TO
SECURE SENATOR JOE MANCHON'S
VOTE FOR THAT LEGISLATIVE
PACKAGE, MAJORITY LEADER, CHUCK
SCHUMER, MADE EVER EFFORT TO
INCLUDE THE PRIORITY OF SENATOR
MANCHON'S REFORM OF THE
PERMITTING PROCESS FOR ENERGY
PROJECTS AS PART OF THE YEAR-END
FUNDING DEAL IN THIS CASE THE
C.R.
A SERIES OF VOTES HAVE BEEN
UNDERWAY THIS WEEK AND AFTER
SIGNIFICANT OPPOSITION FROM
CERTAIN PARTS OF THE LEFT AND
RIGHT, SENATOR MANCHON PULLED
HIS REFORMS AND THE SENATE MOVED
FORWARD ON THEIR FIRST
PROCEDURAL VOTE IN FAVOR OF
MOVING THE C.R. ALONG AND THAT
PASSED LAST NIGHT IN A VOTE OF
72-23.
SO FINAL VOTES TO PASS THE C.R.
HAVEN'T HAPPENED YET BUT ARE
EXPECTED SOON.
WE ARE READING THE SENATE IS
EXPECTED TO VOTE TOMORROW AND
THEN HOPEFULLY THE HOUSE WILL
FOLLOW SHORTLY THEREAFTER AHEAD
OF FRIDAY'S DEADLINE.
SO PERMITTING REFORM ISN'T THE
ONLY LEGISLATION THAT TRIED TO
HITCH A RIGHT ON THE C.R., A
CLEAN FDA USER FEE
RE-AUTHORIZATION WILL BE
ATTACHED TO THE C.R.
THE CURRENT AUTHORIZATION
EXPIRES ON SEPTEMBER 30 AS WELL.
REPORTING LAST WEEK INDICATED
THAT MAJORITY LEADER MITCH
McCONNELL AND RICHARD BURR WERE
OWE POSED TO THE USER FEE BE
ATTACHED TO THE C.R. SO IT'S A
CLEAN RE-AUTHORIZATION AND IT
MEANS SEVERAL PROVISIONS WE WERE
TRACKING WILL NOT BE INCLUDED AT
THIS POINT.
THAT INCLUDES THE GIVE KIDS A
CHANCE ACT WHICH WOULD REQUIRE
FDA NEW AUTHORITY TO REQUIRE
PEDIATRIC STUDY PLANS FOR
COMBINATIONS OF THERAPIES UNDER
CERTAIN CIRCUMSTANCES WHEN BOTH
THERAPIES TARGET MOLECULAR
ALTERCATIONS PRESENT IN
CHILDHOOD CANCERS.
THE BILL WAS ATTACHED TO THE
HOUSE PASSED FDA PACKAGE
HOWEVER, HAD NOT YET BEEN
INCORPORATED IN THE SENATE
PACKAGE.
SIMILARLY, SEVERAL PROVISIONS
DIRECTED TOWARD FDA THAT AIM TO
INCREASE DIVERSE ENROLLMENT IN
CLINICAL TRIALS ARE ALSO
INCLUDED IN THE HOUSE PACKAGE
BUT NOT IN THE SENATE.
SO THESE PROVISIONS AGAIN WILL
NOT BE INCLUDED IN THIS C C.R.
AT THIS TIME BUT THERE'S A
HANDFUL OF AUTHORITIES BEING
RE-AUTHORIZED FOR THE C.R. UNTIL
MID DECEMBER.
THERE STILL MAY BE A CHANCE FOR
POLICY PROVISIONS TO BE
CONSIDERED AT THAT TIME.
WHILE NOTHING IS A DONE DEAL
THERE SEEMS TO BE A STRONG
DESIRE TO PASS THE C.R. BEFORE
FRIDAY'S DEADLINE.
I NOTICED A QUESTION POPPED UP
IN THE CHAT AND THANK YOU,
MAUREEN, I SEE YOU TYPING IN.
A C.R. IS A CONTINUING
RESOLUTION.
IT'S ESSENTIALLY A SHORT-TERM
WAY TO FUND THE GOVERNMENT AS
CONGRESS CONTINUES TO NEGOTIATE
NEW SPENDING LEVELS FOR FY23.
SO UNTIL DECEMBER 16 ONCE THE
HOUSE AND SENATE APPROVE THIS
CONTINUING RESOLUTION AND THE
PRESIDENT SIGNS IT, ALL FEDERAL
AGENCIES WOULD BE FUNDED AT FY22
LEVELS AND THAT IS CHALLENGING
FOR MANY REASONS YOU SAW AND THE
TABLE WE HAVE PROPOSALS TO
INCREASE NCI AND NIH'S BUDGETS
SO CONTINUED TO BE FUNDED AT
FY22 LEVELS.
CONGRESS ISN'T ABLE TO MOVE THE
PRIORITIES LEVEL TO FUND US AT A
HIGHER LEVEL FOR FY23 SO WE HOPE
IT WILL BE SHORT TERM THROUGH
DECEMBER 16 AND CONGRESS WILL BE
ABLE TO REACH AN AGREEMENT IN
DECEMBER TO PROVIDE THE NEW FY23
FUNDING LEVELS FOR NIH AND NCI
AND ALL FEDERAL AGENCIES.
IF YOU CAN SKIP AHEAD TO SLIDE
5.
I DID WANT TO INCLUDE A BRIEF
STATUS UPDATE ON ARPA-H
LEGISLATIVE EFFORTS.
AS I MENTIONED EARLIER, ARPA-H
RECEIVED ITS FIRST APPROPRIATION
IN FY22.
FOR FY23 THE SENATE IS PROPOSING
FL
FLAT FUNDING AND THE HOUSE
PROPOSED AN INCREASE AND NONE
HAVE CROSSED THE FINISH LINE TO
BE ENACTED INTO LAW AND THE
HEALTH SUBCOMMITTEE HAD AN
ARPA-H ACT THAT PASSED EARLIER
IN THE HOUSE BUT DIFFERS FROM
PROPOSALS IN THE SENATE AND
THERE'S GOT TO BE A FOCUSSED
EFFORT TO DEVELOP A CONSENSUS
PROPOSAL.
ONE OF THE UNRESOLVED DIFFERENCE
WHETHER ARPA-H WILL BE A PART OF
NIH OR A SEPARATE DIVISION
WITHIN HHS.
APPROPRIATORS HAVE DEFERRED TO
THE HHS SECRETARY AND IN FY22
SECRETARY BECERRA TRANSFERRED IT
TO NIH AND COULD TRANSFER
FUNCTIONS, AUTHORITIES AND FUNDS
TO AN AGENCY OR OFFICE WITHIN
HHS.
WE SAW AN ANNOUNCEMENT EARLIER
THIS MONTH OF THE PRESIDENT'S
APPOINTMENT OF DR. RENE
WEGGERSON.
SHE'S A DARPA ALUM WHERE SHE
SERVED AS A PROGRAM MANAGER IN
THE BIOLOGICAL TECHNOLOGIES
OFFICE.
WE HAVE A STAR IN DECEMBER AND
YOU'LL SEE JANUARY 3, THE START
OF THE 118th CONGRESS AND
FOCUSSED ON THE NEXT THREE
MONTHS AND AFTER THE HOUSE AND
SENATE PASS THE C.R., THE HOUSE
WILL DEPART D.C. UNTIL MID
NOVEMBER AFTER THE MIDTERMS IN
NOVEMBER 8.
IN DECEMBER WE'LL BE BUDGET
NEGOTIATION AS CONGRESS WILL
HAVE TO PASS AN OMNIBUS
APPROPRIATIONS BILL THAT COVERS
ALL 12 SUBCOMMITTEE AND FUNDS
THE GOVERNMENT FOR FY23 OR A
COLLECTION OF SMALLER PACKAGES
SOMETIMES REFERRED TO AS
MINI-BUSSES OR ANOTHER C.R.
APPROPRIATORS WOULD LIKE TO
AVOID ANOTHER C.R. AT LOST ONE
THAT WOULD PUSH FINAL DECISION
IN THE NEW CONGRESS IN JANUARY.
THERE ARE SEVERAL SENIOR
APPROPRIATORS IN THE SENATE
RETIRING THIS YEAR SO IT'S A
PARTICULAR PRIORITY FOR THEM
INCLUDING CHAIR AND THE SENATOR
PATRICK LEAHY AND RANKING MEMBER
OF THE LABOR HHS SUBCOMMITTEE
ROY BLUNT OF MISSOURI.
IT WILL BE A BUSY FEW MONTHS IN
MANY WAYS AND BUSY DECEMBER AND
WE HAVE A BETTER SENSE OF WHAT
FY APPROPRIATIONS WILL LOOK LIKE
BY THE END OF THE CALENDAR YEAR.
SO NOW I'LL HAND THINGS OVER TO
MAUREEN TO TALK A BIT MORE ABOUT
OTHER NOTABLE LEGISLATION AND
RECENT CONGRESSIONAL EVENTS.
>>THANK YOU, HOLLY AND TO NCRA
FOR HAVING US THIS AFTERNOON.
I'M GOING IT TALK ABOUT OUR
AUTHORIZING LEGISLATION AND VERY
BRIEFLY IF YOU'RE PRETTY NEW IT
CONGRESS AND FOLLOWING CONGRESS,
APPROPRIATION LEGISLATION
PROVIDES FUNDING FOR FEDERAL
AGENCIES.
AUTHORIZING LEGISLATION IS
AUTHORITIES AND PROGRAMS ACROSS
FEDERAL AGENCIES.
I'M GOING START WITH BRIEF
OVERVIEW OF TWO BIG PIECES OF
LEGISLATION THAT WERE ENACTED IN
AUGUST.
THEN I'LL TALK A LITTLE BIT
ABOUT WHAT YOU MIGHT WANT TO BE
WATCHING FOR THIS WEEK AND THEN
FOLLOWING WITH SOME INFORMATION
ABOUT WHAT TO WATCH PARTICULARLY
AFTER THE ELECTION FOR THE REST
OF THIS SESSION OF CONGRESS.
SO THE CHIPS AND SCIENCE ACT AND
INFLATION REDUCTION ACT WERE
ESSENTIALLY NEGOTIATED SIDE BY
SIDE OVER THE SUMMER.
NEITHER HAVE PROVISION ARE
DIRECTLY RELATED TO NIH BUT
THEY'RE DEFINITELY OF INTEREST
TO THE SCIENTIFIC COMMUNITY.
THE CHIPS AND SCIENCE ACT IS A
BIPARTISAN PIECE OF LEGISLATION.
IT WAS A BIG PRIORITY FOR BOTH
REPUBLICANS AND DEMOCRATS TO
MOVE LEGISLATION THAT INVEST IN
THE U.S. SEMICONDUCTOR INDUSTRY
WHICH THIS BILL DOES.
IT ALSO RE-AUTHORIZES THE
NATIONAL SCIENCE FOUNDATION AT A
MUCH HIGHER APPROPRIATIONS LEVEL
THAN WE'VE SEEN IN THE PAST.
IT ALSO HAS MANY PROVISIONS
RELATED TO EXPAND THE GEOGRAPHIC
DIVERSITY OF NATIONAL SCIENCE
FOUNDATION GRANTEES.
THE INFLATION REDUCTION ACT IS A
MUCH MORE PARTISAN BILL AND
MOVED WITH THE RE KCONCILIATION
PROCESS WHICH MEANS IT WAS ABLE
TO PASS WITHOUT REPUBLICAN VOTES
AND REFLECTS DEMOCRATIC
PRIORITIES.
THERE ARE MANY TAX PROVISIONS IN
THE INFLATION ACT BUT OF NOTE
FOR NCRA WE WANTED TO FLAG THAT
FOR THE FIRST TIME THE INFLATION
REDUCTION ACT ALLOWS MEDICARE TO
NEGOTIATE ON CERTAIN
PRESCRIPTION DRUG PRICES AND
ALSO EXTENDS THE ABILITY TO USE
ACA SUBSIDIES THROUGH 2025.
THE AFFORDABLE CARE ACT
SUBSIDIES FOR INFLATION.
AS HOLLY NOTED, THE FDA USER-FEE
RE-AUTHORIZATION HITCHED A RIDE
ON THE PROVISION AND THERE'S
CHANGES THAT ARE SET TO EXPIRE
WITH THE CONTINUING RESOLUTION
AND THAT WILL GIVE CONGRESS
ANOTHER OPPORTUNITY TO REN
RENEGOTIATE AND LOOK INTO
PROVISIONS AND POTENTIALLY
ADDING THE ABILITY FOR THE FDA
TO REGULATE DIETARY SUPPLEMENTS
AND COSMETICS AS WELL AS
POTENTIALLY CHANGES TO THE
ACCELERATED APPROVAL PROCESS FOR
THERAPIES.
THIS WEEK HOWEVER, CONGRESS IS
BUSY NOT JUST LOOKING AT THE
CONTINUING RESOLUTION BUT
SEVERAL AUTHORIZING BILLS.
THERE'S 32 BILLS THAT THE HOUSE
IS GOING LOOKING AT THIS
AFTERNOON AND POTENTIALLY VOTING
ON.
ONE THAT WE WANT TO FLAG IS THE
RE-AUTHORIZATION FOR THE SMALL
BUSINESS INNOVATION RESEARCH AND
TRANSFER PROGRAMS.
THIS STAND ALONE BILL WOULD
REAUTHORIZE THE PROGRAMS THROUGH
THE END OF FISCAL YEAR 2025.
AT SOME POINT CONGRESS WILL NEED
IT TAKE UP THE NATIONAL DEFENSE
AUTHORIZATION ACT.
THIS PROVIDES AUTHORITIES AND
AUTHORIZES PROGRAMS FOR THE
DEPARTMENT OF DEFENSE INCLUDING
THE CDMRP THE MEDICAL RESEARCH
PROGRAM WHICH DOES INCLUDE SOME
FUNDING FOR CANCER RESEARCH
THROUGH DOD.
AFTER THE ELECTION WE'LL BE
WATCHING TO SEE MANY TOPICS THAT
CONGRESS MIGHT TAKE UP AS HOLLY
MENTIONED, THERE MAY BE AN
OFFICIAL AUTHORIZATION FOR
ARPA-H.
THERE MIGHT BE MOVEMENT ON
PANDEMIC PREPAREDNESS, COVID-19
AND MONKEY POX RELIEF,
TELEHEALTH CONTINUATION AND
EXPANSION MAKING THE
FLEXIBILITIES DURING COVID
PERMANENT AND PROPOSALS RELATED
TO CLINICAL TRIALS ACCESS AND
INCLUSION.
WE'LL BE UPDATING YOU HOPEFULLY
IN THE NEW YEAR WITH SOME OF
THOSE TOPICS.
SHIFTING GEARS A LITTLE BIT AS
HOLLY MENTIONED, WE WANTED TO
SHARE INFORMATION ON RECENT
CONGRESSIONAL EVENTS.
WE WERE VERY EXCITED TO HOST
SECRETARY BECERRA, HHS REGION 3
DIRECTOR ALEX STANFORD WELLS
MARYLAND SENATORS AND
REPRESENTATIVE TROLM FOR A VISIT
TO THE NCI LABS IN JULY.
YOU'LL SEE THE GROUP TOURING THE
LAB WHERE THEY LEARNED ABOUT THE
PATIENT-DERIVED MODELS
REPOSITORY.
NOVEMBER IS CHILDHOOD CANCER
MONTH AND IT'S ON IMPLEMENTING
THE CHILDHOOD CANCER STAR ACT,
WE WORKED WITH SUBJECT MATTER
EXPERTS IN THE DIVISION OF
CANCER TREATMENT AND DIAGNOSIS
AND THE DIVISION OF CANCER
CONTROL POPULATION SCIENCES TO
PRESENT A WEBINAR ON
IMPLEMENTATION OF THE NCI
PROVISIONS OF THE STAR ACT.
THESE WONDERFUL EXPERTS PROVIDED
INFORMATION ON NCI-SUPPORTED BIO
BANKING PROJECTS CANCER
SURVIVORSHIP AWARDS.
THE WEBINAR RECORDING AND SLIDES
WILL BE AVAILABLE ON OAR'S
WEBSITE BUT IF YOU WANT IT IN
THE MEANTIME FEEL FREE TO REACH
OUT TO ME OR HOLLY OR OAR.
LAST WEEK WE HAD TWO EVENTS
FOCUSSED ON CHILDHOOD CANCER AND
THE DIRECTOR OF THE OFFICE OF
CANCER SURVIVORSHIP PRESENTED AT
THE SUMMIT ON THE HILL AND ALL
SIX CURRENT AND INCOMING
CO-CHAIRS OF THE CHILDHOOD
CANCER CAUCUS DID ATTEND AND
PRESENT.
ANOTHER PRESENTER IN ADDITION
THERE WAS THE WHITE HOUSE
MOONSHOT COORDINATOR.
AND HELPED ORGANIZE AND PRESENT
THE NEXT DAY AT THE CHILDHOOD
MOONSHOT CANCER FORUM AND
DR. STANNIC THE DIRECTOR OF THE
DIVISION OF CANCER EPIDEMIOLOGY
AND GENETICS AND THE INCOMING
CCI DIRECTOR ALSO PRESENTED AT
THE FORUM AND WE WANTED TO FLAG
THAT MEMBER DR. WENGER
PARTICIPATED IN A PANEL ON
IMPLEMENTATION OF THE STAR ACT.
THE OTHER PANELS FEATURED IN THE
FORUM FOCUSSED ON THE RACE FOR
CHILDREN ACT AS WELL AS THE
CCCDI AND NAVIGATION FOR
PEDIATRIC CANCERS.
WE'RE HAPPY TO ANSWER ANY
QUESTIONS HAVE YOU ABOUT
APPROPRIATIONS, ARPA-H, ANYTHING
ELSE ON YOUR MIND RELATED TO
CONGRESS.
>>WE PROBABLY HAVE TIME FOR ONE
QUESTION BECAUSE WE WANT TO GET
ON OUR NEXT SPEAKER DOES ANYONE
HAVE ANY QUESTIONS AT THIS TIME?
>>YOU CAN REACH OUT TO US AND
IF WE RAISED THROUGH TOO MUCH
CONGRESSIONAL JARGON WE'RE HAPPY
TO TALK OFFLINE FOR ANY
QUESTIONS YOU HAVE.
>>I APPRECIATE THAT AND THE
WORK FOLLOWING WHAT'S GOING ON
AND I KNOW NEXT MEETING WILL BE
EVEN BUSIER.
I APPRECIATE YOUR HARD WORK AND
FOR TALKING TO US ABOUT WHAT'S
GOING ON.
>>THANK YOU, HOLLY AND MAUREEN.
YOU WIN THE AWARD FOR GOOD
COMMUNICATION DESPITE
TECHNOLOGICAL CHALLENGES.
WE APPRECIATE YOUR PERSEVERANCE.
>>THANK YOU.
>>GREAT.
SO NEXT UP WE HAVE A VERY
SPECIAL GUEST DR. CATHERINE
YOUNG ASSISTANT DIRECTOR FOR
CANCER MOONSHOT ENGAGEMENT AND
POLICY AT THE WHITE HOUSE OFFICE
OF SCIENCE AND TECHNOLOGY
POLICY.
WE'VE ALL BEEN REALLY EXCITED
ABOUT THE MOONSHOTS AND THE
RELAUNCH.
I JUST THANK YOU DR. YOUNG FOR
COMING TO SPEAK WITH US.
>>DR. YOUNG SHOULD BE JOINING
MOMENTARILY.
IF WE CAN SIT TIGHT FOR A MOMENT
AND TO ROUND BACK ON HOLLY AND
MAUREEN'S PRESENTATION, I
APOLOGIZE I THINK THEY WERE
COVERING SOME IMPORTANT CONTENT
AND THE VISUALS THEY PREPARED
WELL ILLUSTRATE THE CONTENT WELL
PARTICULARLY HOW THE PROCESS
WORKS IN THE FEDERAL GOVERNMENT.
I WANTED TO FLAG THAT AS THAT'S
AN IMPORTANT EVERY GREEN ISSUE
FOR THE ADVOCACY COMMUNITY TO
UNDERSTAND AND WE'LL MAYBE TRY
TO COVER THAT IN OUR NEXT BOARD
MEETING OR DO SOMETHING SPECIAL
SO YOU GUYS CAN INDEED HAVE A
CHANCE TO LISTEN TO HOLLY AND
SEE THE GRAPHIC OF HOW THE
PROCESS WORKS.
THERE WAS A HAND IN ORGANIZING
THE CONFERENCE AND SEVERAL NCRA
MEMBERS WERE A PART OF THAT.
MAUREEN MENTIONED VICKY AND ALSO
DAN
DANIELLE WAS A MODERATOR.
IT WAS A NICE EVENT TO SEE THE
ADVOCACY COMMUNITY INTERACTING
ON SOME OF THESE IMPORTANT
ISSUES WITHIN THE CHILDHOOD
CANCER SPACE.
>>IS VICKY HERE?
>>SHE DID NOT.
SHE'S IN ANOTHER PEDIATRIC
CANCER MEETING BUT I THINK IT'S
NICE FOR EVERYONE TO SEE HOW
ADVOCATES WEAR MULTIPLE HATS AND
PERFORMING DOUBLE DUTY AND AS
MANY PLACES AS THEY CAN BE AT
ANY GIVEN TIME.
>>I WAS GOING ASK IF SHE CAN
TELL US ABOUT IT SO MAYBE NEXT
TIME GIVEN ENOUGH TIME I'D LOVE
TO HEAR.
>>ABSOLUTELY.
I KNOW WE ARE TRACKING DOWN
DR. YOUNG.
ANNIE, WE'RE WINGING IT HERE, DO
YOU WANT TO JUMP DOWN TO THE
AGENDA AND DO SOME OF THE ITEMS
THAT ARE THE ADMINISTRATIVE
ITEMS WE WERE GOING TO DO AFTER
DR. YOUNG'S PRESENTATION?
>>I DON'T WANT TO GET TOO MUCH
IN THE INTRODUCTIONS YET IN CASE
SHE POPS UP THE FLOOR'S GOING GO
STRAIGHT OVER AND WE'LL DO THE
RE-INTRODUCTION AGAIN.
WE DO NEED TO VOTE TO APPROVE
THE MEETING SUMMARY FOR THE 86th
MEETING.
THE SUMMARY WAS INCLUDED IN THE
BOARD MATERIALS THAT WERE
E-MAILED EARLIER THIS WEEK.
I'M GOING CALL FOR A MOTION TO
APPROVE THOSE MEETING SUMMARIES.
THAT MEETING SUMMARY.
DO I HAVE SOMEONE TO MAKE A
MOTION
>>I MOTION.
>>THANKS, NICOLE.
AND NOW THAT WE HAVE A MOTION ON
THE FLOOR, DO WE HAVE SOMEONE TO
SECOND THE MOTION?
>>SECOND.
>>I'LL CALL FOR NCRA BOARD
MEMBERS TO APPROVE.
IF YOU APPROVE PLEASE SAY AYE.
>>AYE.
>>HEARING NO OBJECTIONS THE
SUMMARY FOR THE 86th MEETING IS
FINALIZED AND APPROVED.
YEA.
DO WE HAVE THE SLIDE FOR THE
PROPOSED MEETING DATES?
DR. YOUNG IS HERE.
WE'RE PLEASED TO HAVE CATHERINE
YOUNG THE ASSISTANT DIRECTOR FOR
THE CANCER MOONSHOT ENGAGEMENT
AND POLICY AT THE WHITE HOUSE
OFFICE OF SCIENCE AND TECHNOLOGY
POLICY.
WE'RE VERY EXCITED ABOUT THE
MOONSHOT'S RELAUNCH AND CAN'T
WAIT TO HEAR MORE FROM YOU,
DR. YOUNG.
THANK YOU SO MUCH FOR JOINING
US.
>>THANK YOU SO MUCH AND THANK
YOU TO THE NCI FOR PROVIDING
THIS OPPORTUNITY FOR ME TO BE IN
FRONT OF YOU AS THE COUNCIL OF
RESEARCH ADVOCATES TO SHARE WITH
YOU A LITTLE BIT ABOUT WHERE
WE'VE COME FROM AND WHERE WE'RE
GOING WITH THE CANCER MOONSHOT.
I WANTED TO START WITH THE QUOTE
FROM PRESIDENT BIDEN ON THE DAY
THE CANCER MOONSHOT WAS
RE-IGNITED IN THE BIDEN-HARRIS
ADMINISTRATION AND SAID I
COMMITTED TO THIS FIGHT WHEN I
WAS VICE PRESIDENT.
IT'S ONE OF THE REASONS OF WHY I
FRANKLY RAN FOR PRESIDENT.
LET THERE BE NO DOUBT, NOW THAT
I AM PRESIDENT, THIS IS A
PRESIDENTIAL WHITE HOUSE
PRIORITY, PERIOD.
END QUOTE.
I WANTED TO START WITH THIS
BECAUSE I WANTED US TO FRAME THE
CONVERSATION WITH THE
UNDERSTANDING THE CANCER
MOONSHOT ARE NOT JUST WORDS BUT
BELIEVES IT'S A PRESIDENTIAL
PRIORITY.
IT WAS SPOKEN IN FEBRUARY AND IN
MARCH IN THE STATE OF THE UNION
THIS YEAR THE PRESIDENT AGAIN
MENTIONED THE CANCER MOONSHOT
AND INCLUDED IT IN THE UNITY
AGENDA THE AGENDA OF BEING ABLE
TO BRING THE COUNTRY TOGETHER
AND I WANTED TO PROVIDE THAT
CONTEXT IN TERMS OF HOW
IMPORTANT THE CANCER MOONSHOT IS
NOT ONLY TO THE ADMINISTRATION
BUT TO THE PRESIDENT.
WITH THE RE-IGNITION OF THE
CANCER MOONSHOT CAME TWO
AUDACIOUS GOALS.
ONE IS TO REDUCE THE TOGETHER
RATE FROM CANCER FROM 50% OVER
NEXT 25 YEARS AND THE SECOND IS
TO IMPROVE THE EXPERIENCE OF
PEOPLE AND THEIR FAMILIES LIVING
WITH AND SURVIVING CANCER.
BY DOING THIS AND MORE ENDING
CANCER AS WE KNOW IT.
PEOPLE SAY THESE ARE AUDACIOUS
GOALS AND YES, WE'RE NOT CALLED
THE CANCER MOONSHOT FOR NO
REASON BUT BELIEVE THEY ARE
DOABLE AND SO DOES THE
PRESIDENT.
THE REASON IS BECAUSE OF THE
ADVANCES WE'VE SEEN THROUGH THE
COVID PANDEMIC AND CHANGES IN
CULTURE WE'RE STARTING TO SEE IN
MEDICINE AND SCIENCE AND
INNOVATION AND TECHNOLOGICAL
ADVANCEMENTS IN THE PAST TWO
DECADES HAS BEEN ASTOUNDING AND
THAT TYPE OF ADVANCEMENT IS ONLY
GOING TO ACCELERATE EVEN MORE
MORE IN THE FUTURE AND BELIEVE
THEY'RE DOABLE GOALS.
THESE ARE WORDS YOU MIGHT HAVE
HEARD THE PRESIDENT SAY.
HE SAYS THEM ALL THE TIME.
WHEN WE STARTED WITH THE CANCER
MOONSHOT WE TOOK THOSE WORDS,
END CANCER AS WE KNOW IT, AND
DISTILLED DOWN WHAT WE KNOW
ABOUT CANCER TODAY.
WE CAME DOWN WITH SEVEN PILLARS
OF ACTS.
THESE AREN'T NECESSARILY PILLARS
OF WORK OR FOCUS MORE SO THIS
WAS OUR WAY OF DISTILL IING DOW
AND WE SAID WHAT DO WE KNOW
ABOUT CANCER TODAY AND WE OFTEN
DIAGNOSIS TOO LATE AND BRINGS TO
SCREENING AND EARLY DETECTION
ACTIONS.
WE STILL HAVE FEW WAYS TO
EFFECTIVELY TREAT CANCER SO WE
THINK ABOUT PREVENTION A LOT.
WE STILL HAVE STARK INEQUITIES
BASED ON RACE, REGION AND
RESOURCES.
OF COURSE ADDRESSING EQUITIES
THROUGH DIAGNOSIS AND
SURVIVORSHIP WILL BE KEY AND
YOU'LL SEE THIS THROUGH
EVERYTHING WE DO IN THE CANCER
MOONSHOT.
WE STILL KNOW TOO LITTLE ABOUT
WHY SOME TREATMENTS WORK FOR
SOME PATIENT AND NOT OTHERS AND
GOES IN ALIGNMENT WITH PRECISION
MEDICINE AND WANT TO TARGET
TREATMENTS TO THE RIGHT PATIENTS
AND THIS OF COURSE WILL BE A
BICK ACTION FOR US.
-- A BIG ACTION FOR US.
WE STILL LACK STRATEGIES FOR
DEVELOPING TREATMENTS FOR SOME
CANCERS AND THIS IS WHERE WE SEE
THE DEADLIEST, THE RAREST
CANCERS INCLUDING CHILDHOOD
CANCERS START TO BUBBLE TO THE
TOP.
THIS IS ONE BIG PRIORITY AREA
FOR US.
WE DON'T DO ENOUGH TO HELP
FAMILIES AND PATIENTS IN THE
AFTER MATH OF CANCER AND HOW
WANT TO PROVIDE SUPPORT FOR
FAMILIES AND CAREGIVERS AS TAY
TRAVERSE THIS CANCER JOURNEY
TOGETHER.
AND LASTLY, WE DON'T LEARN
ENOUGH FROM MOST PATIENT'S
EXPERIENCES AND THIS IS KEY TO
EVERYTHING WE DO.
WE WANT TO LEARN MORE FROM
PATIENTS.
AS WE EVOLVE IN THE CANCER
MOONSHOT WITH VISION, ACTION AND
IDEAS ARE DRAWN FROM THE PATIENT
COMMUNITY AND PEOPLE ASK US YOU
IDENTIFY WHAT YOU WANT TO FOCUS
ON BASED ON THIS COMPREHENSIVE
PORTFOLIO, HOW DO YOU DO IT?
WE ARE ACTUALLY HAVE A ROUTINE
AND WE SEE OURSELVES AS A TEAM
OR DEPARTMENT OR AGENCY.
WE'RE A WHOLE OF GOVERNMENT
APPROACH TO ATTACKING CANCER AND
TO EXECUTE ON THIS THE PRESIDENT
BROUGHT TOGETHER WHAT HE CALLS
THE CANCER CABINET WHICH IS
CABINET SECRETARY LEVELS OF OVER
20 DIFFERENT AGENCIES AND
DEPARTMENTS THAT COME TO THE
TABLE TO TALK AND TO DESIGN
SOLUTIONS FOR DIFFERENT CANCER
COMPONENTS OF THAT JOURNEY.
SO I JUST HERE ON THE SLIDE HAVE
DEPARTMENTS AND AGENCIES LIST
AND WHY WOULD YOU HAVE
DEPARTMENT OF LABOR ON THERE AND
THE REASON WHY WE BRING ALL
THESE DIFFERENT AGENCIES
TOGETHER AT THE TABLE IS BECAUSE
THEY ALL BRING DIFFERENT
RESOURCES, DIFFERENT SCALES,
DIFFERENT PERSPECTIVES AND
THEREFORE DIFFERENT SOLUTIONS TO
THE CANCER JOURNEY.
SO IF WE'RE GOING
COMPREHENSIVELY TACKLE CANCER WE
NEED TO MAKE SURE THAT WE'RE
FILLING ALL THE GAPS AND
BRINGING ALL THESE PLAYERS TO
THE TABLE IS KEY IN BEING ABLE
TO DO THAT.
WHAT THE CANCER CABINET HAS DONE
IS IDENTIFIED FIVE AREAS IN
WHICH THEY CAN EXECUTE EITHER
POLICY REFORM OR PROJECTS,
RELATED TO THESE FIVE AREAS.
WHAT'S REALLY IMPORTANT FOR US
TO TAKE THIS LARGE COMPREHENSIVE
PROBLEM AND DISTILL IT DOWN FOR
THE CANCER CABINET TO TACKLE
MORE EFFECTIVELY.
YOU'LL SEE THE FIVE AREAS OF THE
CANCER CABINET AND THIS IS
THROUGH A LOT OF A LOT OF
DISCUSSIONS ON DEPUTY SIDE TO
COME TO THE TABLE TO BRING IDEAS
AND BROUGHT TOGETHER OVER 100
IDEAS THAT ARE EITHER IN
IDEATION STAGE OR ALREADY IN
PROGRESS THAT WILL TACKLE CANCER
ON THAT SPECTRUM.
SO HERE ARE OUR FIVE AREAS.
NUMBER ONE, IS TO CLOSE THE
SCREENING GAP.
OBVIOUSLY, WE KNOW WE LOST ABOUT
10 MILLION SCREENINGS DURING
COVID AND IT'S IMPERATIVE WE AS
A GOVERNMENT SPEED THE PROCESS
TO CATCH UP ON THE SCREENINGS
BECAUSE WE ARE GOING TO SEE THE
DEVASTATING CONSEQUENCES OF THE
LOSS OF SCREENINGS COMING DOWN
THE PIPELINE SOON.
NUMBER TWO IS ADDRESSING AND
UNDERSTANDING ENVIRONMENTAL AND
TOXIC EXPOSURES.
AS MORE SCIENCE AND STUDIES COME
ABOUT OUR ENVIRONMENT WE ARE
STARTING TO UNDERSTAND HOW
IMPORTANT IT IS TO TACKLE OUR
ENVIRONMENT WHEN IT COMES CANCER
PARTICULARLY ON THE REGULATORY
SIDE.
YOU'LL SEE WORK EVOLVE
PARTICULARLY AROUND THE FDA AND
EPA IN THIS REGARD.
NUMBER THREE IS DECREASE THE
IMPACT OF PREVENTIBLE CANCERS.
WE KNOW THERE ARE CANCERS WE
HAVE THE TOOLS TO TACKLE RIGHT
NOW.
WE CAN THINK OF HPV RELATED
CANCERS AND ANOTHER CANCER
RELATED TO HEPATITIS C AND WE
HAVE TO GET THE COMMUNITIES AND
WE MEAN ALL COMMUNES ACCESS TO
THESE TOOLS THAT ARE SO CRUCIAL
TO BE ABLE TO REALLY STOP THESE
CANCERS IN THEIR TRACK.
AND HERE'S RESEARCH THAT STARTED
IN THE LABS THROUGH THE
DISCOVERY PIPELINE TO THE
CLINICAL TRIALS AND THEN TO THE
COMMUNITIES THEMSELVES.
WE FEEL IT'S NECESSARY TO GET
THE TO THE PIPELINE QUICKER THAN
WE ARE SEEING TODAY AND THIS
SPECIFICALLY IS FOCUSSED ON THE
DEADLIEST CANCERS AND THE RAREST
CANCERS WHICH ARE CHILDHOOD
CANCER.
NUMBER FIVE THE CANCER CABINET
IS TO AGAIN FOCUS DOWN ON
IMPROVING THE EXPERIENCE OF
CAREGIVERS AND THIS GOES BEYOND
NAVIGATION.
THIS IS A KEY COMPONENT TO THE
EXPERIENCE BUT WE ARE ALSO
TALKING ABOUT HAVING PATIENTS
BEING EMPOWERED BY DATA AND THE
KNOWLEDGE THAT THEY NEED IN
ORDER TO JOURNEY THROUGH THAT
CANCER JOURNEY IN THE BEST
POSSIBLE WAY.
AND ALSO IN THIS PARTICULAR ONE
AND GOING BACK TO THE PREVIOUS
POINT ABOUT ALWAYS INCLUDING
PATIENTS AND ADVOCATES IS MAKING
SURE THEY HAVE A SEAT AT THE
TABLE AS WE HAVE THESE
CONVERSATIONS AROUND CHANGING
THE ECOLOGY ECO SYSTEM WE HAVE
TO TO HAVE THEM AND HAVE THE
OPPORTUNITY TO DO SO.
THESE ARE THE FIVE AREAS FOR THE
CANCER CABINET A NUMBER OF
ANNOUNCEMENTS THAT HAVE ALREADY
BEEN MADE.
THESE ARE SOME ANNOUNCEMENTS
FROM THE AGENCIES TACKLING
DIFFERENT AREAS.
I DON'T MEAN FOR YOU TO SQUINT
AT THE FONT AND $215 MILLION WAS
AWARDED THROUGH THE CDC FOR
CANCER CONTROL AND CANCER
PREVENTION PROGRAMS.
AND WE HAVE $100 MILLION TOWARDS
GLOBAL INTERDISCIPLINARY TEAMS
FOR RESEARCHERS TO TACKLE SOME
OF THE GREATEST CHALLENGES
AROUND CANCER.
WE ALSO HAD CMS, THE CENTERS FOR
MEDICARE AND MEDICAID ANNOUNCE
NATIONAL COVERAGE DETERMINATION
TO EXPAND COVERAGE FOR LUNG
CANCER SCREENINGS AND THE V.A.
EXPANDING THEIR BENEFITS FOR
VETERANS THAT CAN NOW CLAIM
PRESUMPTIVE BENEFITS FOR SEVERAL
CANCER AS PART OF THE PACT ACT.
I WANTED TO SHOW YOU THIS TIME
LINE BECAUSE IT'S NOT ONLY THING
WE USE.
WE TRY TO ATTACK THE CANCER
LANDSCAPE IN MANY MANY WAYS.
THROUGH THE TIME LINE HELPFULLY
YOU CAN SEE SOME OF THE
DIFFERENT ASPECTS THAT ARE
DIFFERENT TO JUST THE CANCER
CABINET.
OF COURSE, HAVING THE PRESIDENT
RE-IGNITE THE CANCER MOON SHOT
SHARE WITHIN THE STATE OF THE
UNION INCLUDED IN THE UNITY
AGENDA WAS THE FIRST VERY FIRING
ALL CYLINDERS IN TERMS OF FOCUS
DOWN ON CANCER IN THE COUNTRY.
AND FROM THERE WE BROUGHT
TOGETHER THE COMMUNITY AND
BROUGHT TOGETHER THE ADVOCATES
AND THE RESEARCHERS, THE
PATIENTS AND THEIR FAMILIES AND
HELD ABOUT 10 DIFFERENT
COMMUNITY CONVERSATIONS WHERE WE
ASKED THEM WHAT ARE THE BIGGEST
CHALLENGES AND THE GAPS YOU SEE
TODAY AND FROM THOSE
CONVERSATIONS, WE RECONVENED
DIFFERENT ADVOCATES AND PATIENTS
AND DIFFERENT STAKEHOLDERS FOR
GOALS WHERE WE BASICALLY
UNVEILED SOME OF OUR GOALS AND
SAID, OKAY, WE'RE ALL HEADED IN
THE RIGHT DIRECTION.
THEN IN PARALLEL TO THIS WE HAVE
THE CANCER CABINET WORKING VERY
HARD IN EXECUTING THEIR IDEAS
AROUND ACTION ITEMS AND WE
UNVEILED A PRIORITY ACTION STEPS
WHICH I MENTIONED JUST
PREVIOUSLY.
WE HAD THE SIGNING OF THE PACT
ACT AND THE INFLATION REDUCTION
ACT WHICH DECREASES HEALTH CARE
COSTS FOR MANY CANCER PATIENTS
SO DRIVING AND SUPPORTING THE
KEY LEGISLATION PIECES THAT
ALIGN WITH THE CANCER MOONSHOT
IS ALSO A VERY IMPORTANT LEVER
THAT WE PULL.
AND PRESIDENT BIDEN GAVE REMARKS
AT THE J.F.K. LIBRARY IN
BROADCAST ON THE 60th
ANNIVERSARY OF PRESIDENT
KENNEDY'S MOONSHOT SPEECH.
DURING THE REMARKS HE AGAIN MADE
SEVERAL ANNOUNCEMENTS OF NEW
INITIATIVES WE'RE DRIVING FOR IT
AS WELL AS NEW PROGRESS OF THE
CANCER CABINET HAS MADE.
AND JUST LAST FRIDAY WE BROUGHT
TOGETHER THE CHILDHOOD CANCER
COMMUNITY TOGETHER TO NOT ONLY
HIGHLIGHT THE PROGRESS THAT THE
BIDEN ADMINISTRATION IS MAKING
BUT ALSO TO USE AS AN
OPPORTUNITY TO ENGAGE WITHIN THE
COMMUNITIES BOTH THE PATIENT AND
THE ADVOCACY COMMUNITY BECAUSE
IT IS A TWO-WAY CONVERSATION.
WE CAN IN THE JUST SPEAK.
WE HAVE TO LISTEN AS WELL AND
THIS WAS A REALLY AMAZING
OPPORTUNITY FOR US TO DO THAT.
AND JUST LOOKING A LITTLE BIT
MORE FORWARD FOR YOU, NEXT MONTH
WE ARE LAUNCHING NATIONAL BREAST
AND CERVICAL ROUNDTABLES THROUGH
THE AMERICAN CANCER SOCIETY AND
YOU WILL ALSO SEE IN THE VERY
NEAR TERM FUTURE PUBLIC-PRIVATE
PARTNERSHIP TO CATALYZE THESE
PARTNERSHIPS.
I WANT TO FOCUS BRIEFLY ON THE
PRESIDENT'S REMARKS HE GAVE TWO
WEEKS AGO ON THE ANNIVERSARY OF
PRESIDENT KENNEDY'S MOONSHOT
REMARKS.
I WANT TO HIGHLIGHT A QUOTE FROM
THE SPEECH AND HE SAID, I
BELIEVE WE CAN USHER IN THE SAME
UNWILLING TO POSTPONE THE SAME
PURPOSE TO ORGANIZE AND MEASURE
THE BEST OF OUR ENERGIES AND
SKILLS TO END CANCER AS WE KNOW
IT AND EVEN CURE CANCER ONCE AND
FOR ALL.
I WANT TO FOCUS REALLY ON HIS
CORRALLING THE NATIONAL PURPOSE
TOGETHER BECAUSE I THINK AGAIN
THIS REALLY SIGNIFIES THE ENTIRE
APPROACH OF THE CANCER MOONSHOT
IS NOT JUST ONE OR TWO PEOPLE OR
ORGANIZATIONS OR TEAMS, BUT
REALLY AN ENTIRE COMMUNITY AND
NATION EFFORT.
AND TO HIGHLIGHT THE INITIATIVE
THE PRESIDENT ANNOUNCED DURING
THE REMARKS WHICH FALL IN LINE
WITH THE WORK WE'RE TRYING TO
EXECUTE AND SUPPORT THE IDEAS
GOING FORWARD THE PRESIDENT
ANNOUNCED THE INAUGURAL DIRECTOR
OF ARPA-H WHICH IS A NEW AGENCY
THAT WILL DRIVE BIOMEDICAL
INNOVATION TO SUPPORT THE HEALTH
FOR ALL AMERICANS AND LAUNCH A
BIO MANUFACTURING INITIATIVE AND
CANCER WILL PLAY A PART IN THAT.
AND MADE COMMITS.
I WANTED TO REITERATE THE
AMAZING WORK OUT OF NCI ALIGNED
WITH THE CANCER MOONSHOT.
AND SUPPORT THE RESEARCH CENTERS
OF EXCELLENCE AND UNDER TABLING
MULTI-CANCER DETECTION TESTS
WHICH COULD REVOLUTIONIZE CANCER
SCREENINGS BY A SINGLE BLOOD TEF
AND ANNOUNCE THE MOONSHOT
SCHOLARS PROGRAM WHICH WILL HELP
USHER IN NEW EARLY CAREER GRANT
OPPORTUNITIES TO INVEST IN THE
NEXT GENERATION OF CANCER
RESEARCHERS.
AND SIGNED INTO THE LAW THE
INFLATION REDUCTION ACT PUT CAP
ON OUT-OF-POCKET EXPENSES.
AND MAKING TAX-SUPPORTED
RESEARCH AVAILABLE TO THE
U.S. PUBLIC AT NO COST AND THIS
WILL AFFECT MORE THAN AND TO
NOTE THIS WAS DRIVEN BY THEN
VICE PRESIDENT BIDEN'S VISION IN
2016 WHO REQUIRES ALL NCI
STUDIES TO FOLLOW THIS POLICY
AND NOW WE HAVE THE REST OF THE
FEDERAL GOVERNMENT CATCH UP SO
WAY TO GO NCI ON ALL THE WORK
YOU'VE DONE ON THAT.
AND IT'S NOT JUST ABOUT THE
FEDERAL GOVERNMENT AND
ENVELOPING THE COMMUNITY TO WORK
TOWARDS A SINGULAR MISSION.
WE WORKED AND DR. BIDEN HAS HER
OWN INCREDIBLE POWERFUL PLATFORM
WHEN IT COMES TO CANCER.
WE WORK VERY CLOSELY WITH HER
AND HOW TO BEST UTILIZE THE
PLATFORM TO ADVANCE THE CANCER
MOONSHOT GOALS.
WE HAVE A DIRECT LINE OF ACCESS
AND ALLOW A DIRECT LINE OF
ACCESS FOR THE COMMUNITY TO THE
CANCER MOONSHOT WHERE WE CAN
SUBMIT PROJECTS AND COMMITMENTS
TO US AND WE READ EVERY SINGLE
ONE OF THEM AND HAVE THE ABILITY
TO COMMUNICATE WITH THOSE WHO
ARE REACHING OUT TO US TO
EVALUATE FURTHER THE IDEAS THEY
PROPOSED.
AND WE USED A FACT SHEET THAT
LISTS ALL THE PRIVATE SECTORS
STEPPING UP TO THE CALL TO
ACTION AND YOU'LL SEE IN THE
NEXT FEW MONTHS SEVERAL CALLS TO
ACTION GOING OUT.
AS I MENTIONED WE ENCOURAGE AND
CATALYZE PUBLIC-PRIVATE
PARTNERSHIP WE'RE AT A UNIQUE
PLACE WHERE WE SIT AT THE 30,000
FOOT VIEW AND WE'RE CONSTANTLY
HAVING CONVERSATIONS WITH THE
COMMUNITY WHETHER THEY'RE
ACADEMICS, ONCOLOGISTS,
CHEMISTS, BIO TECHNOLOGISTS AND
BE ABLE TO START TO SEE WHERE WE
CAN CONNECT THE DOTS WHERE
PEOPLE ARE WORKING TOGETHER AND
MAYBE SHOULD ALL KNOW EACH OTHER
OR IF WE MAKE AN INTRODUCTION,
SOMETHING MAGICAL HAPPENS, NOT
ALL THE TIME BUT SOMETIMES THEY
DO AND INTRODUCE PEOPLE TO THOSE
AND BE ABLE TO AMPLIFY AND
SUPPORT THE WORK THEY'RE DOING.
FINALLY, I WANT TO MENTION THE
PRESIDENT HAS A PRESIDENT'S
CANCER PANEL.
IT'S A GROUP OF VOLUNTEERS WHO
COME TOGETHER TO ADVISE THE
PRESIDENT SPECIFICALLY AROUND
CANCER RESEARCH AND FEDERAL
SPENDING.
THE PRESIDENT RECENTLY APPOINTED
THREE NEW MEMBERS AND MANY MAY
FIND THE NAMES FAMILIAR.
AND I WANTED TO SHARE EXCITING
THINGS DOWN THE PIPELINE.
THE CANCER MOONSHOT WAS
INITIALLY IGNITED AND HAD ABOUT
EIGHT MONTHS TO EXECUTE WORK
BEFORE THE END OF THE
ADMINISTRATION.
THIS TIME AROUND WITH THE
PRESIDENT AT THE HELM AND MORE
OF THAN EIGHT MONTHS TO EXECUTE
ON WORK WE WILL BE EXPANDING OUR
MISSION GLOBALLY AS WELL.
SO WE REALLY DO BELIEVE THAT IN
ORDER TO FULLY REALIZE THE
PRESIDENT'S VISION, IT IS UP TO
THE CANCER MOONSHOT TO BENEFIT
PATIENTS AND FAMILIES AROUND THE
WORLD.
WE HAVE TAKEN SEVERAL STEPS TO
START ENTERING INTO THE SPACE
AND HAVE BEEN WORKING CLOSELY
WITH THE NCI GLOBAL HEALTH
AGENCY AND WHAT WE'VE DONE IS
BROUGHT TOGETHER AGENCIES THAT
ALL WORK IN SOME CAPACITY
GLOBALLY AND TOUCH CANCER TO
BRING EVERYBODY TO THE TABLE AND
SEE WHAT ARE YOU DOING AND HOW
CAN WE WORK TOGETHER TO WORK
COHESI
COHESIVELY.
WE HAD COUNTRIES EXPRESS
INTEREST IN MOUs AND THERE'S
SEVERAL CONVERSATIONS HAPPENING
FOR MOUs SPECIFICALLY AROUND
CANCER.
WE HELD A U.K.-U.S. CANCER
RESEARCH SUMMIT WHERE TOP
SCIENTISTS CAME TOGETHER TO
IDENTIFY AREA WHERE THEY MIGHT
BE ABLE TO WORK TOGETHER SO A
LOT OF WORK HAPPENING AND WILL
BE HAPPENING AND I THINK YOU'LL
START TO SEE IT IN 2023 MORE
SOLIDIFIED PLANS AROUND A GLOBAL
PLAN WELL.
AND ONE MUCH MY MOST FAME QUOTES
SO FAR THAT IS PRESIDENT BIDEN
WHEN HE GAVE REMARKS AT THE
J.F.K. LIBRARY HE SAID AMERICA
CHOSE TO GO TO THE ROOM NOT
BECAUSE IT WAS EASY BUT BECAUSE
IT WAS HARD AND THE CHALLENGE IS
ONE WE'RE UNWILLING TO POSTPONE.
TODAY, OUR MOONSHOT IS ENDING
CANCER AS WE KNOW IT AND IT'S
SOMETHING WE CAN DO TOGETHER.
SO I THINK HE'S RIGHT AND
BECAUSE WE WANT TO DO IT
TOGETHER I WANT TO SHARE WITH
YOU MY E-MAIL INFORMATION AS
WELL AS THE WEBSITE IN WHICH YOU
ARE WELCOME TO SHARE WITH YOUR
NETWORKS WHERE PEOPLE CAN SUBMIT
THEIR OWN IDEAS, THEIR OWN
STORIES, THEIR OWN COMMITMENTS
IF THEY HAVE ANY AND LIKE I
SAID, WE WILL READ EVERY SINGLE
ONE OF THEM AND USE THAT AS AN
OPPORTUNITY TO CONTINUE TO REACH
OUT TO OUR COMMUNITIES.
I WANTED TO JUST TAKE A MOMENT
TO SAY THANK YOU AGAIN NOR
OPPORTUNITY TO PROVIDE AN UPDATE
AND I'M OF COURSE HAPPY TO TAKE
ANY QUESTIONS.
>>THANK YOU FOR THE
COMPREHENSIVE OVERVIEW AND
APPRECIATE YOUR TIME TO COME
TALK WITH US.
I WANT TO DOUBLE CHECK ON HOW
MUCH TIME YOU HAVE TO ANSWER A
FEW QUESTIONS.
>>IF I COULD LEAVE HERE AT 2:55
I HAVE A HARD 3:00.
>>I'LL TAKE CHAIR'S PREROGATIVE
AND ASK THE FIRST QUESTION.
I WON'T GO OVER ALL THE EXCITING
THINGS YOU SPOKE ABOUT AND I'M
VERY EXCITED YOU ARE HAVING
CONVERSATIONS WITH PATIENTS AND
ADVOCATES IN THE CONVERSATION
AND FORUMS AND SUMMITS MY
QUESTIONS IS ARE THERE ONGOING
RELATIONSHIPS WITH ADVOCATES
INVOLVED IN THE MOONSHOT AND IS
THERE REPRESENTATION FROM
ADVOCATES IN THOSE PERSISTENT
POVERTY AREAS OR UNDER SERVED
POPULATIONS WITH HIGH MORTALITY?
>>THANK YOU FOR THAT QUESTION,
ANNIE.
IT IS A VERY GOOD QUESTION AND
ONE WE GET A LOT AND THINK ABOUT
A LOT TOO.
THIS RE-IGNITION OF THE CANCER
MOONSHOT HASN'T SEEN THE LAUNCH
OF A PATIENT TASK FORCE OR A
SPECIFIC WORKING GROUP
SPECIFICALLY ON PATIENTS AND I
WILL SAY THE REASON FOR THAT IS
BECAUSE AT THE CORE PATIENTS ARE
INCLUDED IN EVERYTHING THAT WE
DO.
EVERY DISCUSSION, EVERY
CONVENING, EVERY FORUM, EVERY
BRIEFING, THERE NOT QUESTION
THAT PATIENTS, CAREGIVERS,
FAMILIES AND ADVOCATES WILL BE A
PART OF THOSE CONVERSATIONS.
AND WE SPEND THE MAJORITY OF OUR
DAYS HAVING CONVERSATIONS WITH
THE COMMUNITIES AND ESPECIALLY
LEARNING ABOUT THOSE IN
COMMUNITIES THAT NEED THE MOST
HELP AND SO WE ARE CONSTANTLY
LEARNING ABOUT THIS LANDSCAPE
AND IT IS WHY IT IS SO IMPORTANT
AND FOR ANY OF YOU ON THE CALL
HERE TODAY, WHY IT'S SO
IMPORTANT FOR ANYONE TO BE ABLE
TO REACH OUT TO US.
WE DON'T WANT TO PIGEONHOLE WHO
CAN AND CANNOT CONTACT US OR
WHAT ORGANIZATIONS WE ENGAGE
WITH.
THE DOOR'S OPEN.
WE'LL SPEAK WITH ANYONE AND
EVERYONE WHO CONTACTS US BECAUSE
WE UNDERSTAND SOMETIMES WE LEARN
MORE FROM THOSE CONVERSATIONS
THAN IN OTHER TIMES.
I HOPE THAT FRAMES A LITTLE BIT
BETTER IN TERMS OF HOW WE THINK
ABOUT PATIENTS THAT THEY ARE A
NATURAL INCLUSION IN EVERYTHING
WE DO AND DON'T HAVE A SEPARATE
COMPONENT FOR THEM BECAUSE THEY
ARE JUST PART OF THE CANCER
MOONSHOT INHERENTLY.
>>THANKS FOR THAT.
THAT'S HELPFUL IN HOPING THE
PEOPLE WHO HAVE A HARD TIME
ACCESSING CANCER SERVICES,
PERIOD, DON'T HAVE THE SAME
BARRIER TO ACCESS THE WHITE
HOUSE.
THINGS ARE REALLY IN CERTAIN
POPULATIONS THINGS ARE REALLY
TOUGH AND OUTREACH MAY BE
REQUIRED SO THEY KNOW THEY'RE
WELCOMED.
>>ABSOLUTELY.
>>I APPRECIATE YOU INCLUDING
THAT.
NICOLE, YOU HAD YOUR HAND UP.
>>YES, HI.
THANK YOU SO MUCH.
THAT WAS REALLY GREAT TO HEAR
THE GOALS AND VISION FOR THE
CANCER MOONSHOT.
ONE THING YOU BRIEFLY MENTIONED
BUT I TRIGGERED MY MEMORY, I'LL
BE ATTENDING THE CANCER GRAND
CHALLENGES MEETING ON HOW
TECHNOLOGY'S WINNING THE FIGHT
AGAINST BRAIN CANCER.
I WAS CURIOUS AS TO IF YOU CAN
TALK ABOUT HOW THE CANCER GRAND
CHALLENGES FITS INTO OR DOESN'T
FIT INTO THE CANCER MOONSHOT AND
THIS IS GOING TO BE CONTINUING.
IS THIS -- DO YOU HAVE A VISION
FOR THAT.
IS THAT PART OF THE PARTNERSHIP
YOU WERE TALKING ABOUT?
>>THANK YOU FOR THAT, NICOLE.
I THINK THE GRAND CHALLENGE IS
ONE SMALL COMPONENT.
I THINK WOULD BE AN EXAMPLE OF
THE GREAT PARTNER REALLY THE
GRAND CHALLENGES BROUGHT
TOGETHER NCI AND CANCER RESEARCH
U.K. TO PULL TOGETHER THIS
PARTICULAR CHALLENGE AROUND
CANCER AND REALLY AT THE CORE
THE MISSION WAS TO BRING IDEAS
FROM INTERDISCIPLINARY TEAMS
THAT WOULD COLLABORATE ACROSS
BOUNDARIES.
IT ALIGNS SO WELL WITH SO MANY
THINGS WE'RE TRYING TO
ACCOMPLISH.
ONE IS ENSURING TEAMS DON'T HAVE
TO WORK TOGETHER JUST HERE IN
THE UNITED STATES BUT THERE'S
ENCOURAGEMENT FOR INTERNATIONAL
TEAMS TO EXIST AND UTILIZING THE
CANCER RESEARCH SPOKE TO BE ABLE
TO ANSWER THESE DIFFICULT
QUESTIONS AND AGAIN
MULTI-DISCIPLINARY TEAMS GIVEN
$25 MILLION OVER NEXT FIVE
YEARS, WHICH IS A FAIRLY
SIGNIFICANT SIZE AWARD AND WE'RE
VERY HOPEFUL TO SEE WHAT COMES
OUT OF THOSE AWARDS.
THANK YOU FOR YOUR QUESTION.
>>THANK YOU.
>>WE PROBABLY HAVE TIME FOR ONE
MORE BEFORE WE HAVE TO LET
DR. YOUNG RUN TO THE NEXT CALL.
>>THANK YOU FOR YOUR TIME AND
VERY INFORMATIVE PRESENTATION
TODAY.
YOU ARE FROM THE OFFICE OF
SCIENCE AND TECHNOLOGY BUT THE
SEVEN PILLARS OF ACTION OFFLINE
DON'T EXPLICITLY CALL
TECHNOLOGY.
MAYBE TAKE ONE OF THEM LIKE THE
PATIENT EXPERIENCE AND SAY A FEW
WORDS ABOUT HOW TECHNOLOGY CAN
POTENTIALLY BRIDGE THAT GAP AND
HELP ACCELERATE THE CANCER
MOONSHOT INITIATIVE.
>>I THINK TECHNOLOGY THOUGH MAY
NOT HAVE BEEN EXPLICITLY CALLED
OUT IS INHERENT IN MANY OF THOSE
PRIORITIES.
WE CAN THINK ABOUT DRIVING
ACCELERATION OF THAT CANCER
PIPELINE OR BEING ABLE TO FOCUS
ON RARE OR DEADLY OR CHILDHOOD
CANCERS.
THE PATIENT EXPERIENCE HAVING
PATIENT NAVIGATION AND HOW
TECHNOLOGY PLAYS A ROLE IN THAT
BIOMEDICAL AND BIO TECHNOLOGY IN
TERMS OF NEW AND INNOVATIVE
TREATMENTS.
I DO THINK THAT TECHNOLOGY IS
GOING TO BE A PLAYER IN SO MANY
DIFFERENT ASPECTS AND THEY COME
TO US FROM ALL DIFFERENT ANGLES.
SO WE VERY MUCH AGAIN WHEN WE
ARE SPEAKING TO OUR
STAKEHOLDERS, OUR SPEAKING TO
THE TECHNOLOGIES FROM ALL
SECTORS FROM DESIGNING ACTS
THROUGH BIO TECHNOLOGY OF NEW
TREATMENTS AND HOW THEY MIGHT
ALL COALESCE TOWARDS THIS
PARTICULAR MISSION.
HOPEFULLY THAT ANSWERS YOUR
QUESTION BUT WE CERTAINLY SEE
TECHNOLOGY PLAYING A PARALLEL
ROLE AS SCIENCE DOES TRUTHFULLY
BECAUSE THOSE TWO HAND IN HAND
TOGETHER ARE CERTAINLY GOING TO
PUSH THE NEEDLE AND WE'RE TRYING
TO BE THE POWER BEHIND THAT TO
JUST GET THEM TO MOVE FASTER.
>>WELL, THANK YOU SO MUCH,
DR. YOUNG FOR COMING AND
SPENDING TIME WITH US AND JUST
GIVING US THIS OVERVIEW AND
CLARIFY A LOT OF THINGS WE'VE
BEEN HEARING AND HAVING
EXCITEMENT HERE ABOUT THE
DETAILS IT'S VERY EXCITING AND
WE CAN'T WAIT TO SEE THE NEXT
STEPS AND WHAT'S TO COME.
>>THANK YOU, ANNIE.
I APPRECIATE THAT.
I SEE MANY FAMILIAR FACES ON
THIS SO I'M SORRY I CAN'T SAY HI
INDIVIDUALLY BUT JUST A PLEASURE
TO BE WITH YOU HERE TODAY.
ANNIE, IF YOU WOULDN'T MIND
SHARING MY E-MAIL IF ANYONE
DIDN'T CATCH IT AND HAPPY TO
CONTINUE ANY CONVERSATION OR
QUESTIONS YOU MAY HAVE AND THANK
YOU FOR YOUR TIME TODAY.
>>THANKS AGAIN AND THANK YOU
FOR BEING OPEN AND AVAILABLE.
>>THANK YOU.
THANKS SO MUCH.
APPRECIATE IT.
>>THANK YOU SO MUCH.
>>THANK YOU.
>>SO FOR THE BOARD WE'RE GOING
TO GO A LITTLE OVER TIME JUST TO
WRAP THINGS UP A LITTLE BIT.
SO IF YOU CAN HANG ON FOR JUST A
LITTLE BIT HERE.
HERE OUR DATES.
AMY, DO YOU WANT TO TALK ABOUT
THIS?
>>WE'RE AT THE TAIL END OF THE
MEETING AND WANT TO DO A LITTLE
HOUSEKEEPING.
THESE ARE THE DATES THAT WE ARE
SORT OF FLAGGING FOR YOU NOW FOR
2023 MEETINGS.
WE LIKE TO HAVE THEM SET FOR THE
INCOMING YEAR AND PUT THEM ON
YOUR CALENDAR.
THERE'S NOT REALLY ANYTHING ELSE
YOU NEED TO DO AT THIS POINT.
IF YOU HAVE A POTENTIAL CONFLICT
CERTAINLY LET US KNOW BUT WE'RE
MINDFUL THAT YOU ALL ARE MOVING
IN ALL SORTS OF DIFFERENT
DIRECTIONS AND WE FEEL HONORED
TO HAVE YOUR TIME FOR THIS BOARD
SO WE WANT TO GIVE YOU ADVANCED
NOTICE OF WHEN WE'RE PLANNING TO
GET TOGETHER IN 2023.
>>AND IF WE HAVE TIME, WE DID
NOT GET TO MEET OUR NEW MEMBERS
VERY BRIEFLY LIKE WE DO IN THE
PAST.
SO BEFORE WE ADJOURN, DO WE
HAVE -- CAN WE TAKE A MINUTE SO
EVERYONE CAN GIVE THEIR QUICK
INTRODUCTION AND
>>THAT WOULD BE GREAT.
BOB, THIS IS ALWAYS TRICKY
BECAUSE EVERYBODY'S SORT OF
TALKING SQUARES ARE DIFFERENT.
ON MY SCREEN, BOB IS THE FIRST
OF OUR INCOMING MEMBERSHIP ON MY
SCREEN.
SO BOB, CAN WE START WITH YOU?
IF EVERYONE CAN INTRODUCE
THEMSELVES AND SPEAK A LITTLE
BIT ABOUT WHERE YOUR COMING FROM
AND YOUR PASSION.
THAT WOULD BE HELPFUL.
>>I'M FROM NEW YORK AND I'VE
BEEN IN THE CANCER WORLD A LONG
TIME AS A SURVIVOR.
A GOOD CHUNK OF MY CAREER HAS
BEEN IN LOCAL CANCER SUPPORT
ORGANIZATION.
THE LAST SEVERAL YEARS I WORKED
AT CORNELL UNIVERSITY AND MY
FOCUS IS CONNECTING TRAINEES AND
BASIC CANCER RESEARCH WITH THE
LOCAL CANCER COMMUNITY.
I'D LIKE TO BE THAT BRIDGE AND
IN CELL BIOLOGY AND CONNECTICNG
THOSE TO THE REAL LIFE OF
CANCER.
>>THANK YOU, BOB.
>>I'M MARTY CHAKOIAN AND A
PROSTATE CANCER SURVIVOR AND
HAVE SUPPORT GROUPS HERE IN
SEATTLE WHERE I LIVE.
I CHAIR THE PATIENT ADVOCATES
COMMITTEE FOR THE PACIFIC
NORTHWEST PROSTATE CANCERS WHICH
IS A COALITION OF FRED HUTC
HUTCHINSON CENTERS.
I WAS BOARD CHAIR OF US TOO
INTERNATIONAL.
IT WAS A PROSTATE CANCER
ADVOCACY AND EDUCATION
ORGANIZATION AND MERGED AND NOW
ON THE BOARD OF ZERO.
I'M PRETTY ACTIVE IN THE
PROSTATE CANCER ALLIANCE WHICH
IS AN AMERICAN NEUROLOGICAL
ASSOCIATION CONSORTIUM OF
PROSTATE CANCER NON-PROFIT
REPRESENTATIVES.
THAT'S ME.
THANKS.
I'M EXCITED TO BE HERE.
>>I WAS DIAGNOSED WITH THYROID
CANCER AT 13.
I ALSO HAVE A SCIENTIFIC
BACKGROUND.
MY Ph.D. IS IN MOLECULAR BIOLOGY
AND GENETICS WHERE I STUDIED
THYROID CANCER IN HOPKINS AND
I'M AT FRIENDS OF CANCER
RESEARCH A NON-PROFIT PATIENT
ADVOCACY ORGANIZATION IN D.C.
WE WORK TO DEVELOP POLICY AND IN
THE REGULATORY SCIENCE PHASE FOR
CANCER CLINICAL TRIALS.
AND INVOLVED IN A NUMBER OF
THYROID CANCER SPECIFIC
ORGANIZATION GROUPS AS WELLED
FOUNDING MEMBER OF THE
PARTNERSHIP FOR NTRAP THAT WORKS
WITH A COUPLE OF THEIR PROGRAMS.
EXCITED TO BE PART OF THIS
GROUP.
>>I'M EXCITED TO BE BACK ON THE
BOARD.
IT'S GREAT TO SHARE THIS
OPPORTUNITY WITH ALL OF YOU.
YOU GUYS ARE MY ROCK STARS
BECAUSE WE'RE MAKING THINGS
HAPPEN FOR PATIENTS.
I'M CURRENTLY WITH CER
ROUNDTABLE AN CANCER AND WAS
PART OF THE AMERICAN CANCER
SOCIETY NINE YEARS IN THE
RESEARCH DEPARTMENT.
ALSO DIAGNOSED WITH STAGE 3
BREAST CANCER IN 2007 WHEN I WAS
34.
SO IT'S A BLEND OF PROFESSIONAL
AND PERSONAL LIKE MOST OF US AND
I WOULD SAY WHEN I WAS DIAGNOSED
MY KIDS ARE 3 AND 5 AND NOW
THEY'RE IN COLLEGE.
PEOPLE SAID ARE YOU UPSET TO BE
AN EMPTY NESTER?
I'M SO GRATEFUL TO WITNESS THIS
CHAPTER, I CAN'T TELL YOU.
A PLEASURE TO SERVE WITH YOU ALL
AND GOOD TO HE SEE YOU, AMY.
AN ANNIE, I TOLD YOU ON THE CHAT
IF THIS IS YOUR FIRST MEETING AS
CHAIR, YOU'RE KILLING IT.
NATHANIEL.
>>I'M COMING TO YOU FROM UTAH
AND THE MOUNTAIN WEST LARGELY.
I'VE DONE A LOT OF WORK AS A
PATIENT ADVOCATE AND NOW IN THE
SPACE OF CLINICAL TRIALS AND HOW
THEY RELATE TO A LOT OF OUR
RURAL AREAS AND I'LL EVEN GO AS
FAR AS TO A RURAL AREAS OF LESS
THAN SEVEN PEOPLE PER SQUARE
MILE AND IT'S COMMON WHERE I'M
FROM.
A LOT OF THAT VERY SMALL TOWN
PREVENTION FOR SCREENING,
ADVOCACY AND CLINICAL TRIALS AND
FOLKS ON TRIAL AND KNOW WHAT
THEIR RIGHTS ARE SO --
>>TERRIFIC.
WELCOME ALL OF YOU.
HAVE I MISSED ANYONE?
I'M LOOKING AT MY SCREEN.
>>I'VE BEEN CHECKING OFF THE
NAMES OF OUR NEW MEMBERS AND
RETURNING MEMBERS.
I THINK THAT WAS EVERYONE, AMY.
WELL, IF WE HAVE NO OTHER
BUSINESS AT THIS TIME I JUST
WANT TO THANK EVERYONE FOR
ATTENDING TODAY AND GOING
THROUGH THE TECHNICAL
DIFFICULTIES AND WRITING
EVERYTHING OUT AND THANK YOU FOR
HELPING TO MAKE MY FIRST TIME
CHAIRING VERY EASY.
I APPRECIATE ALL OF YOU.
MUCH APPRECIATION TO AMY AND
VINCENT AND I GUESS THIS IS IT.
THE MEETING OF THE NCRA IS
ADJOURNED AND WE'LL SEE YOU NEXT
TIME.
>>THANK YOU, AMY AND THANK YOU
FOR YOUR DISCUSSION AND THANK
YOU FOR THE ADVOCACY OFFICE FOR
GETTING US ALL HERE.
TALK TO YOU ALL SOON.
>>THANK YOU, BYE-BYE.